A. ORIGIN OF THE REPORT

A1		Name of contracting Party:
		Canada
A3k		Web page
		https://www.canada.ca/en/health-canada.html
1		Period of reporting:
	1	Start date
		January 2020
	1	End date
		January 2023

B1. TOBACCO CONSUMPTION

B1		Prevalence of tobacco use
B11		Smoking prevalence in the adult population (all) (Please provide prevalence data for total adult population, and identify the age considered, e.g. 15 years old and over, 18-64 years; see B112)
1_SQ001		Current smokers
	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	1_SQ002	11.8 MALE [Average number of the most-consumed smoking tobacco product used per day]
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 8.5
	2_SQ002	FEMALE [Average number of the most-consumed smoking tobacco product used per day]
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	3_SQ002	10.2 TOTAL (males and females) [Average number of the most-consumed smoking tobacco product used per day]
1_SQ001		Daily smokers
	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 8.7
	1_SQ002	MALE [Average number of the most-consumed smoking tobacco product used per day]
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 6.6
	2_SQ002	FEMALE [Average number of the most-consumed smoking tobacco product used per day]
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	3_SQ002	7.8 TOTAL (males and females) [Average number of the most-consumed smoking tobacco product used per day]

	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		3.0
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		1.9
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		2.5
1_SQ001		Former smokers
	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		23.2
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 21.9
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		22.7
1_SQ001		Never smokers
	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		65.0
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		69.6
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		67.1
B111		Please indicate the smoking tobacco products included in calculating prevalence for question B11:
		Cigarettes
1_SQ001		Please indicate the age range to which the data used to answer question B11 refer:
	1_SQ001	Age range [From]
		15
	1_SQ002	Age range [To]
B113A		Please indicate the year of the data used to answer question B11:
		2021
B113B		Please indicate the source of the data used to answer question B11:
		Canadian Tobacco and Nicotine Survey 2021: https://www.canada.ca/en/health- canada/services/canadian-tobacco-nicotine-survey.html
SQ001		Please provide the definitions of "current smoker", "daily smoker", "occasional smoker", "former smoker" and "never smoker" used in this report.

	SQ001	Current smoker
		Current Smoking: Includes people who smoke daily and people who smoke occasionally, determined from the responses to the question "During the past 30 days, how often did you smoke cigarettes?" (Please note: In the future Health Canada does note use "smoker" in our terminology and would appreciate if the FCTC retired this term and instead used "people who smoke").
	SQ002	Daily smoker
		Daily Smoking: Refers to those who respond "daily" to the question "During the past 30 days, how often did you smoke cigarettes?"
	SQ003	Occasional smoker
		Occasional Smoking: Refers to those who respond "less than daily, but at least once a week" or "less than once a week, but at least once in the past month" to the question "During the past 30 days, how often did you smoke cigarettes?"
	SQ004	Former smoker
		Former Smoking: Refers to those who respond "not at all" to the question "During the past 30 days, how often did you smoke cigarettes?" and "yes" to the question "Have you smoked at least 100 cigarettes (about 4 packs) in your life?"
	SQ005	Never smoker
		Never Smoking: Refers to those who respond "not at all" to the question "During the past 30 days, how often did you smoke cigarettes?" and "no" to the question "Have you smoked at least 100 cigarettes (about 4 packs) in your life?" or "no" to the question "Have you ever smoked a whole cigarette?"
B115		Please provide a brief explanation of the trend in smoking prevalence in the adult population in the past two years or since submission of your last report.
		The prevalence of current cigarette smoking among Canadians aged 15 years and older in 2021 was 10.2% [95% CI: 9.4, 11.0] (3.2 million), unchanged from 2020. Please note: Health Canada would appreciate if in the future the FCTC questionnaire was updated to include "men/women", and "girls/boys" everywhere rather than "male/female" (sex at birth).
B12a_B12x1		Smoking prevalence in the adult population (by age groups)(If data are available, please provide prevalence data by age group, and identify the age group considered, preferably by 10-year categories, e.g. 25-34, 35-44 years)
	B12a_B12x1	MALES - current smokers1 [Range - start age]
		25
	B12a_B12x3	MALES - current smokers1 [Range - end age]
		44
	B12a_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		14.2
	B12b_B12x1	MALES - current smokers1 [Range - start age]
		45
	B12b_B12x3	MALES - current smokers1 [Range - end age]
	B12b_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12b_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 11.1

B12c_B12x3	MALES - current smokers1 [Range - end age]
B12c_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B12d_B12x1	MALES - current smokers1 [Range - start age]
B12d_B12x3	MALES - current smokers1 [Range - end age]
B12d_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B12e_B12x1	MALES - current smokers1 [Range - start age]
B12e_B12x3	MALES - current smokers1 [Range - end age]
B12e_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B12ee_B12x1	MALES - current smokers1 [Range - start age]
B12ee_B12x3	MALES - current smokers1 [Range - end age]
B12ee_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B12eee_B12x1	MALES - current smokers1 [Range - start age]
B12eee_B12x3	MALES - current smokers1 [Range - end age]
B12eee_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B12eeee_B12x 1	MALES - current smokers1 [Range - start age]
B12eeee_B12x 3	MALES - current smokers1 [Range - end age]
 B12eeee_B12x 2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B12f_B12x1	FEMALES - current smokers1 [Range - start age]

	25
B12f_B12x3	FEMALES - current smokers1 [Range - end age]
	44
B12f_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	8.6
B12g_B12x1	FEMALES - current smokers1 [Range - start age]
	45
B12g_B12x3	FEMALES - current smokers1 [Range - end age]
 B12g_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	9.5
B12h_B12x1	FEMALES - current smokers1 [Range - start age]
B12h_B12x3	FEMALES - current smokers1 [Range - end age]
B12h_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B12i_B12x1	FEMALES - current smokers1 [Range - start age]
B12i_B12x3	FEMALES - current smokers1 [Range - end age]
B12i_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B12j_B12x1	FEMALES - current smokers1 [Range - start age]
 B12j_B12x3	FEMALES - current smokers1 [Range - end age]
 B12j_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B12jj_B12x1	FEMALES - current smokers1 [Range - start age]
B12jj_B12x3	FEMALES - current smokers1 [Range - end age]
B12jj_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]

B12jjj_B12x1	FEMALES - current smokers1 [Range - start age]
B12jjj_B12x3	FEMALES - current smokers1 [Range - end age]
B12jjj_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B12jjjj_B12x1	FEMALES - current smokers1 [Range - start age]
B12jjjj_B12x3	FEMALES - current smokers1 [Range - end age]
 B12jjjj_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B12k_B12x1	TOTAL (males and females) - current smokers1 [Range - start age]
B12k_B12x3	TOTAL (males and females) - current smokers1 [Range - end age]
B12k_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	11.3
B12I_B12x1	TOTAL (males and females) - current smokers1 [Range - start age]
B12I_B12x3	TOTAL (males and females) - current smokers1 [Range - end age]
B12I_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	10.4
B12m_B12x1	TOTAL (males and females) - current smokers1 [Range - start age]
B12m_B12x3	TOTAL (males and females) - current smokers1 [Range - end age]
B12m_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B12n_B12x1	TOTAL (males and females) - current smokers1 [Range - start age]
B12n_B12x3	TOTAL (males and females) - current smokers1 [Range - end age]
B12n_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]

	-	
	B12o_B12x1	TOTAL (males and females) - current smokers1 [Range - start age]
	B12o_B12x3	TOTAL (males and females) - current smokers1 [Range - end age]
	B120_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B1200_B12x1	TOTAL (males and females) - current smokers1 [Range - start age]
	B1200_B12x3	TOTAL (males and females) - current smokers1 [Range - end age]
	B1200_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12000_B12x1	TOTAL (males and females) - current smokers1 [Range - start age]
	B12000_B12x3	TOTAL (males and females) - current smokers1 [Range - end age]
	B12000_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B120000_B12x 1	TOTAL (males and females) - current smokers1 [Range - start age]
	B120000_B12x 3	TOTAL (males and females) - current smokers1 [Range - end age]
	B120000_B12x 2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B121		Please indicate the smoking tobacco products included in calculating prevalence for question B12:
		Cigarettes
B122A		Please indicate the year of the data used to answer question B12:
		2021
B122B		Please indicate the source of the data used to answer question B12:
		CTNS 2021 https://www.canada.ca/en/health-canada/services/canadian-tobacco-nicotine- survey.html
B123		Please provide a brief explanation of the trend in current smoking prevalence by age group in the past two years or since submission of your last report, if data are available.
		In 2021, the prevalence of current cigarette smoking among Canadian adults aged 25 years and older was 10.8% [95% CI: 9.9, 11.7] (2.8 million), unchanged from 2020.
B13		Prevalence of smokeless tobacco use in the adult population (all) (Please provide prevalence data for total adult population, and identify the age considered in B132, e.g. 15 years old and over, 18–64 years; see B132)

1_B13x1		Males
	1_B13x1	Current users [Prevalence (%) (please include all smokeless tobacco products in prevalen data)]
		0.8
	2_B13x1	Daily users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	3_B13x1	Occasional users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	4_B13x1	Former users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	5_B13x1	Never users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
1_B13x1		Females
	1_B13x1	Current users [Prevalence (%) (please include all smokeless tobacco products in prevalen data)]
	2_B13x1	Daily users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	3_B13x1	Occasional users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	4_B13x1	Former users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	5_B13x1	Never users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
1_B13x1		TOTAL (males and females)
	1_B13x1	Current users [Prevalence (%) (please include all smokeless tobacco products in prevalen data)]
		0.4
	2_B13x1	Daily users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]

	3_B13x1	Occasional users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	4_B13x1	Former users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	5_B13x1	Never users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B131		Please indicate the smokeless tobacco products included in calculating prevalence for question B13:
1_SQ001		Chewing tobacco, pinch, snuff. Please indicate the age range to which the data used to answer question B13 refer:
1_00001		
	1_SQ001	Age range [From]
	1_SQ002	Age range [To]
B133A		Please indicate the year of the data used to answer question B13: 2021
B133B		Please indicate the source of the data used to answer question B13:
		CTNS 2021 https://www.canada.ca/en/health-canada/services/canadian-tobacco-nicotine-survey.html
SQ001		Please provide the definitions of "current user", "daily user", "occasional user", "former user" and "never user" (of smokeless tobacco products) used in this report in the space below.
	SQ001	Current user
		"Current user" is use in the past-30 days.
	SQ002	Daily user
	SQ003	Occasional user
	SQ004	Former user
	SQ005	Never user
B135		Please provide a brief explanation of the trend in smokeless tobacco use in the adult population in the past two years or since submission of your last report.
		In 2021, 0.4% [95% CI: 0.3, 0.6] (137,000) of Canadians aged 15 years and older reported using chewing tobacco in the past 30 days, unchanged from 2020.
B12a_B12x1		Prevalence of smokeless tobacco use in the adult population (current users) by age group (by age groups)(If data are available, please provide prevalence data by age group, and

	identify the age group considered, preferably by 10-year categories, e.g. 25-34, 35-44 years)
B12a_B12x1	MALES - current users2 [Age group (adults)]
	15
B12a_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	3
B12b_B12x1	MALES - current users2 [Age group (adults)]
 B12b_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12c_B12x1	MALES - current users2 [Age group (adults)]
 B12c_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12d_B12x1	MALES - current users2 [Age group (adults)]
B12d_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12e_B12x1	MALES - current users2 [Age group (adults)]
 B12e_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12ee_B12x1	MALES - current users2 [Age group (adults)]
 B12ee_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12eee_B12x1	MALES - current users2 [Age group (adults)]
B12eee_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12eeee_B12x 1	MALES - current users2 [Age group (adults)]
B12eeee_B12x 2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]

B12f_B12x1	FEMALES - current users2 [Age group (adults)]
B12f_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12g_B12x1	FEMALES - current users2 [Age group (adults)]
B12g_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12h_B12x1	FEMALES - current users2 [Age group (adults)]
B12h_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12i_B12x1	FEMALES - current users2 [Age group (adults)]
B12i_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12j_B12x1	FEMALES - current users2 [Age group (adults)]
B12j_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12jj_B12x1	FEMALES - current users2 [Age group (adults)]
B12jj_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12jjj_B12x1	FEMALES - current users2 [Age group (adults)]
B12jjj_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12jjjj_B12x1	FEMALES - current users2 [Age group (adults)]
B12jjjj_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12k_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]

bit tobacco products in prevalence data)] bit B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] bit B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] bit B120000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] bit B120000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] bit B120000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] cl B120000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] cl B120000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)]
tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole and females) - current users2 [Prevalence (%) (please include all smole all smole and females) - current users2 [Prevalence (%) (please include all smole
tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x B12000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B120000_B12x B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products and females) - current users2 [Prevalence (%) (please include all smoltobacco products and females) - current users2 [Prevalence (%) (please include all smoltobacco products and females) - current users2 [Prevalence (%) (please include all smoltobacco products and females) - current users2 [Prevalence (%) (please include all smoltobacco products and females) - current users2 [Prevalence (%) (please include all smoltobacco products and females) - current users2 [Prevalence (%) (please include all smoltobacco products and females) - current users2 [Prevalence (%) (please include all smoltobacco products and females) - current users2 [Prevalence (%) (please include all smoltobacco products and females) - current users2 [Prevalence (%) (please include all smoltobacco products and females) - current users2 [Prevalence (%) (please include all smoltobacco products and females) - current users2 [Prevalence (%) (please include all smoltobacco products and females) - current users2 [Prevalence (%) (please
B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)]
tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole and females) - current users2 [Prevalence (%) (please include all smole all smole and females) - current users2 [Prevalence (%) (please include all smole and females) - current users2 [Prevalence (%) (please include all smole all smol
B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B120000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)]
B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)]
tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x1 B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B1200_B12x1 B1200_B12x1 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B1200_B12x1 B1200_B12x1 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
B120_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
B120_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
B120_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B120_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
bit tobacco products in prevalence data)] bit tobacco products in prevalence data)] bit
B120_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B120_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] 1 TOTAL (males and females) - current users2 [Age group (adults)] 1 TOTAL (males and females) - current users2 [Age group (adults)]
bit tobacco products in prevalence data)] bit tobacco products in prevalence data)] bit
bit b
bit tobacco products in prevalence data)] bit tobacco products in prevalence data)] bit
bit b
bit b
bit b
bit bit bit bit bit b
bit bit bit bit bit b
bit bit bit bit bit b
B120_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B120_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x1 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
B120_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B120_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x1 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
B120_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
B120_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
B120_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
B120_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
B120_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
B120_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B120000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B120000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B120000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B120000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B120000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
tobacco products in prevalence data)] B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B120000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B120000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
B1200_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smoltobacco products in prevalence data)] B120000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)]
B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)]
B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)]
B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)]
B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)]
B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)]
B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)]
B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)]
B1200_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)]
tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole and females) - current users2 [Prevalence (%) (please include all smole all smole and females) - current users2 [Prevalence (%) (please include all smole all smo
tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole and females) - current users2 [Prevalence (%) (please include all smole all smole and females) - current users2 [Prevalence (%) (please include all smole all smo
tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole and females) - current users2 [Prevalence (%) (please include all smole all smole and females) - current users2 [Prevalence (%) (please include all smole all smo
tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole and females) - current users2 [Prevalence (%) (please include all smole and females) - current users2 [Prevalence (%) (please include all smole and females) - current users2 [Prevalence (%) (please include all smole and females) - current users2 [Prevalence (%) (please include all smole all smole and females) - current users2 [Prevalence (%) (please include all smole al
tobacco products in prevalence data)] B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B12000_B12x2 TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole and females) - current users2 [Prevalence (%) (please include all smole all smole and females) - current users2 [Prevalence (%) (please include all smole all smo
B12000_B12x1 TOTAL (males and females) - current users2 [Age group (adults)] B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole and females) - current users2 [Prevalence (%) (please include all smole all smole all smole all smole and females) - current users2 [Prevalence (%) (please include all smole
B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole a
B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole a
B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole a
B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole a
B12000_B12x2 TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole a
tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole)]
tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole)]
tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole)]
tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole)]
tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole)]
tobacco products in prevalence data)] B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole)]
B120000_B12x TOTAL (males and females) - current users2 [Age group (adults)] B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole)
1 B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole)]
1 B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole)]
1 B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole)]
1 B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole)]
1 B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smole)]
B120000_B12x TOTAL (males and females) - current users2 [Prevalence (%) (please include all smol
2 tobacco products in prevalence data)]
B141 Please indicate the smokeless tobacco products included in the answer to question
Flease indicate the shokeless topacco products included in the answer to question
Chewing tobacco, pinch, snuff.
B142A Please indicate the year of the data used to answer question B14:
B142A Please indicate the year of the data used to answer question B14:

B142B		Please indicate the source of the data used to answer question B14:
		Canadian Tobacco, Alcohol and Drugs Survey (CTADS) 2017 English - https://www.canada.ca/en/ health-canada/services/canadian-tobacco-alcohol-drugs-survey/2017-summary.html French- https:/ /www.canada.ca/fr/sante-canada/services/enquete-canadienne-tabac-alcool-et- drogues/sommaire-2017.html English - https://www.canada.ca/en/health-canada/services/canadian- tobacco-alcohol-drugs-survey/2015-summary.html
B143		Please provide a brief explanation of the trend in current use of smokeless tobacco by adult age groups in the past two years or since submission of your last report.
		Overall use of smokeless tobacco remains very low, and is unchanged from the previous report. ?Note that this number should be rounded up. * Moderate sampling variability, interpret with caution.
B15a_B15x1		Tobacco use by ethnic group(s) (please include all smoking or smokeless tobacco products in prevalence data)
	B15a_B15x1	Current users 3 [Ethnic group(s)]
	B15a_B15x2	Current users 3 [MALES - Prevalence (%)]
	B15a_B15x3	Current users 3 [FEMALES - Prevalence (%)]
	B15a_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
	B15b_B15x1	Current users 3 [Ethnic group(s)]
	B15b_B15x2	Current users 3 [MALES - Prevalence (%)]
	B15b_B15x3	Current users 3 [FEMALES - Prevalence (%)]
	B15b_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
	B15c_B15x1	Current users 3 [Ethnic group(s)]
	B15c_B15x2	Current users 3 [MALES - Prevalence (%)]
	B15c_B15x3	Current users 3 [FEMALES - Prevalence (%)]
	B15c_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
	B15d_B15x1	Current users 3 [Ethnic group(s)]
	B15d_B15x2	Current users 3 [MALES - Prevalence (%)]

	B15d_B15x3	Current users 3 [FEMALES - Prevalence (%)]
	B15d_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
	B15e_B15x1	Current users 3 [Ethnic group(s)]
	B15e_B15x2	Current users 3 [MALES - Prevalence (%)]
	B15e_B15x3	Current users 3 [FEMALES - Prevalence (%)]
	B15e_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
B151		Please indicate the tobacco products included in the answer to question B15:
1_SQ001		Please indicate the age range to which the data used to answer question B15 refer:
	1_SQ001	Age range [From]
	1_SQ002	Age range [To]
B153A		Please indicate the year of the data used to answer question B15:
B153B		Please indicate the source of the data used to answer question B15:
B16a_B16x1		Tobacco use by young persons (please include all smoking or smokeless tobacco products in prevalence data)
	B16a_B16x1	BOYS - Current users 4 [Age range] 15-19
	B16a_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)] 3.8
	B16a_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)] #
	B16a_B16x4	# BOYS - Current users 4 [WATER PIPE - Prevalence (%)] #
	B16b_B16x1	BOYS - Current users 4 [Age range]
	B16b_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]

B16b_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16b_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
 B16c_B16x1	BOYS - Current users 4 [Age range]
B16c_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16c_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16c_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
B16d_B16x1	BOYS - Current users 4 [Age range]
B16d_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16d_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16d_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
B16e_B16x1	BOYS - Current users 4 [Age range]
 B16e_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
 B16e_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
 B16e_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
 B16ee_B16x1	BOYS - Current users 4 [Age range]
B16ee_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16ee_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16ee_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
B16eee_B16x1	BOYS - Current users 4 [Age range]

B16eee_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16eee_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16eee_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
 B16eeee_B16x	BOYS - Current users 4 [Age range]
B16eeee_B16x	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16eeee_B16x 3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16eeee_B16x	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
B16f_B16x1	GIRLS - Current users 4 [Age range] 15-19
B16f_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16f_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)] #
B16f_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
B16g_B16x1	# GIRLS - Current users 4 [Age range]
 B16g_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16g_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16g_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
B16h_B16x1	GIRLS - Current users 4 [Age range]
B16h_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16h_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]

B16i	_B16x1 G	GIRLS - Current users 4 [Age range]
B16i	_B16x2 G	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16i	_B16x3 G	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16i	_B16x4 G	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
B16j	_B16x1 G	GIRLS - Current users 4 [Age range]
B16j	_B16x2 G	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16j	_B16x3 G	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16j	_B16x4 G	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
B16j	j_B16x1 G	GIRLS - Current users 4 [Age range]
B16j	j_B16x2 G	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16j	j_B16x3 G	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16j	j_B16x4 G	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
B16jj	j_B16x1 G	GIRLS - Current users 4 [Age range]
B16jj	j_B16x2 G	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16jj	j_B16x3 G	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16jj	j_B16x4 G	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
B16jj	jj_B16x1 G	GIRLS - Current users 4 [Age range]
B16jj	jj_B16x2 G	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16jj	jj_B16x3 G	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]

B16jjjj_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
B16k_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
	15-19
B16k_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	3.3
B16k_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	0.6
B16k_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
	#
B16l_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
B16l_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16l_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16l_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
B16m_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
 B16m_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16m_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16m_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
B16n_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
B16n_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16n_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16n_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
B160_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
B16o_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]

	B16o_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16o_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
	B1600_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
	B1600_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B1600_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B1600_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
	B16000_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
	B16000_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16000_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16000_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
	B160000_B16x 1	TOTAL (boys and girls) - Current users 4 [Age range]
	B160000_B16x 2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B160000_B16x 3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B160000_B16x 4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
B161		Please indicate the tobacco products included in calculating prevalence for question B16:
DACOA		Cigarettes; chewing tobacco, pinch, or snuff; water pipe
B162A		Please indicate the year of the data used to answer question B16:
Dicco		
B162B		Please indicate the source of the data used to answer question B16: CTNS 2021 https://www.canada.ca/en/health-canada/services/canadian-tobacco-nicotine- survey.html
B163		Please provide the definition of "current smoking/tobacco use" used to answer question B16 in the space below.
		Current Smoking: Includes people who smoke daily and people who smoke occasionally, determined from the responses to the question "During the past 30 days, how often did you smoke cigarettes?" Smokeless and waterpipe: includes use in the past-30-days.

B164		Please provide a brief explanation of the trend in tobacco use by young persons in the past two years or since submission of your last report.
SQ001_SQ001		Male
	SQ001_SQ001	Prevalence (%) (please include all smoking tobacco products in prevalence data) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ001_SQ002	Prevalence (%) (please include all smoking tobacco products in prevalence data) [Average number of the most-consumed smoking tobacco product used per day]
	SQ002_SQ001	Average number of the most-consumed smoking tobacco product used per day [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ002_SQ002	Average number of the most-consumed smoking tobacco product used per day [Average number of the most-consumed smoking tobacco product used per day]
	SQ003_SQ001	Occasional smokers [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ003_SQ002	Occasional smokers [Average number of the most-consumed smoking tobacco product used per day]
	SQ004_SQ001	Former smokers [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ004_SQ002	Former smokers [Average number of the most-consumed smoking tobacco product used per day]
	SQ005_SQ001	Never smokers [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ005_SQ002	Never smokers [Average number of the most-consumed smoking tobacco product used per day]
1_1		Use of novel and emerging tobacco and nicotine products
	1_1	Age range [Age range]
	1_2	Age range [Heated tobacco products (HTPs) - Prevalence (%)]
	1_3	Age range [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]

1_4	Age range [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
1_5	Age range [Other products - Prevalence (%)]
2_1	Heated tobacco products (HTPs) - Prevalence (%) [Age range]
2_2	Heated tobacco products (HTPs) - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]
2_3	Heated tobacco products (HTPs) - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]
2_4	Heated tobacco products (HTPs) - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
 2_5	Heated tobacco products (HTPs) - Prevalence (%) [Other products - Prevalence (%)]
3_1	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Age range] 25+
3_2	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]
3_3	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)] 2.6
3_4	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)] 0.5
 3_5	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Other products - Prevalence (%)]
4_1	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Age range]
4_2	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]
4_3	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]
4_4	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Electronic Non- Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
 4_5	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Other products -

		Prevalence (%)]
	5_1	Other products - Prevalence (%) [Age range]
	5_2	Other products - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]
	5_3	Other products - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]
	5_4	Other products - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
	5_5	Other products - Prevalence (%) [Other products - Prevalence (%)]
	6_1	YOUNG PERSONS - Total (boys and girls) [Age range]
	6_2	YOUNG PERSONS - Total (boys and girls) [Heated tobacco products (HTPs) - Prevalence (%)]
	6_3	YOUNG PERSONS - Total (boys and girls) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]
	6_4	YOUNG PERSONS - Total (boys and girls) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
	6_5	YOUNG PERSONS - Total (boys and girls) [Other products - Prevalence (%)]
B171		Please indicate the year and source of the data used to answer question B17. CTNS 2021 https://www.canada.ca/en/health-canada/services/canadian-tobacco-nicotine-survey.html
B172		Please provide a brief explanation of the trends – in adults and in young persons – in the use of novel and emerging tobacco and nicotine products in the past two years or since submission of your last report.
		The prevalence of past-30-day vaping was 12.7% [95% CI: 11.1, 14.4] (262,000) among youth aged 15 to 19 years unchanged from 2020. The prevalence of past-30-day vaping was 3.6% [95% CI: 3.0, 4.2] (944,000) among adults aged 25 years and older unchanged from 2020

B2-B9. HEALTH, SOCIAL AND ECONOMIC INDICATORS

B2	Exposure to tobacco smoke
B21	Do you have any data on exposure to tobacco smoke in your population?
	Yes
B22	Please provide details in the space below (e.g. exposure by gender, at home, in the workplace, on public transport).
	British Columbia (BC) – In British Columbia, 9.6% of people aged 12 and older smoked in 2021. The male smoking rate is 11.5% and female smoking rate is 7.8%. BC does not have data broken down by workplace/home etc. Ontario (ON) – In Ontario, 16% of non-smoking Ontarians aged 12 years and over were exposed to secondhand smoke every day or almost every day in public places restaurants, bars, shopping malls and arenas) over the past month in 2015. Among young nonsmokers aged 12 to 18, 30% (or 293,600) were exposed to secondhand smoke in public places in 2015. New Brunswick (NB) – Youth (grades 6-12) exposed to cigarette smoke at home: Overall: 13.3%; Indigenous: 23.5%; Youth (grades 6-12) Exposed to cigarette smoke in a vehicle, last 7 days: Overall: 18.4%; Indigenous: 32%
B23A	Please indicate the year of the data used to answer question B21: 2021
B23B	Please indicate the source of the data used to answer question B21:
	https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310009610&pickMembers%5B0%5D=1.11 &pickMembers%5B1%5D=3.1&cubeTimeFrame.startYear=2020&cubeTimeFrame.endYear=20218 referencePeriods=20200101%2C20210101 – total https://www150.statcan.gc.ca/t1/tbl1/en/tv.action ?pid=1310009610&pickMembers%5B0%5D=1.11&pickMembers%5B1%5D=3.2&cubeTimeFrame. startYear=2020&cubeTimeFrame.endYear=2021&referencePeriods=20200101%2C20210101 - males https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310009610&pickMembers%5B0%5D =1.11&pickMembers%5B1%5D=3.3&cubeTimeFrame.startYear=2020&cubeTimeFrame.endYear= 2021&referencePeriods=20200101%2C20210101 – females ON – Smoke-Free Ontario Strategy Monitoring Report, Ontario Tobacco Research Unit (using Canadian Community Health Survey Data). NB – New Brunswick Health Council, Student Wellness Survey Grades 6-12. The 2021-2022 edition of the New Brunswick Student Wellness Survey was completed by 42,000 students in grades 6 to 12 between November 2021 and January 2022: https://nbhc.ca/table/substance- use?cuts=NB
B3	Tobacco-related mortality
B31	Do you have information on tobacco-related mortality in your population?
	Yes
B32	What is the estimated total number of deaths attributable to tobacco use in your population?
	47707
B33	If available, please provide any additional information on mortality attributable to tobacco use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction.
	See link in B34B
B34A	Please indicate the year of the data used to answer question B32 and 33:
	2017
B34B	Please indicate the source of the data used to answer questions B32 and B33:
	https://www2.gov.bc.ca/assets/gov/birth-adoption-death-marriage-and-divorce/statistics- reports/annual-reports/2015/pdf/annual-report-2015.pdf - pg 52. Canadian Substance Use Cost and Harms Substance use-attributable deaths counts, Newfoundland and Labrador; Canada -
	https://csuch.ca/publications/CSUCH-Canadian-Substance-Use-Costs-Harms-Report-2020-en.pdf

B41		Do you have information on the economic burden of tobacco use in your population, e.g. the overall cost of tobacco use imposed on your society?
		Yes
B42		Please provide details (e.g. direct (health care-related) and indirect costs and, if possible, the method used to estimate these costs).
		In 2017 the direct and indirect costs of tobacco use were \$12.3 billion.
B43A		Please indicate the year of the data used to answer question B42:
		2017
B43B		Please indicate the source of the data used to answer question B42:
		https://csuch.ca/publications/CSUCH-Canadian-Substance-Use-Costs-Harms-Report-2020-en.pdf
B5		Supply of tobacco and tobacco products (with reference to Articles 6.2(b), 20.4(c), and 15.5)
B51a_B51x1		Licit supply of tobacco products
	B51a_B51x1	Smoking tobacco products [Product]
		Cigarettes
	B51a_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
		Sticks
	B51a_B51x3	Smoking tobacco products [Domestic production]
		13174962288
	B51a_B51x4	Smoking tobacco products [Retail sales]
	B51a_B51x5	Smoking tobacco products [Exports]
		2859430000
	B51a_B51x6	Smoking tobacco products [Imports]
		7745972339
	B51b_B51x1	Smoking tobacco products [Product]
		Fine cut
	B51b_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
		kg
	B51b_B51x3	Smoking tobacco products [Domestic production]
		286490
	B51b_B51x4	Smoking tobacco products [Retail sales]
	B51b_B51x5	Smoking tobacco products [Exports]
<u> </u>	B51b_B51x6	Smoking tobacco products [Imports]
		71277

	B51c_B51x1	Smoking tobacco products [Product]
	B51c_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B51c_B51x3	Smoking tobacco products [Domestic production]
	B51c_B51x4	Smoking tobacco products [Retail sales]
	B51c_B51x5	Smoking tobacco products [Exports]
	B51c_B51x6	Smoking tobacco products [Imports]
	B51cc_B51x1	Smoking tobacco products [Product]
	B51cc_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B51cc_B51x3	Smoking tobacco products [Domestic production]
	B51cc_B51x4	Smoking tobacco products [Retail sales]
	B51cc_B51x5	Smoking tobacco products [Exports]
	B51cc_B51x6	Smoking tobacco products [Imports]
E	B51ccc_B51x1	Smoking tobacco products [Product]
E	B51ccc_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
E	B51ccc_B51x3	Smoking tobacco products [Domestic production]
E	B51ccc_B51x4	Smoking tobacco products [Retail sales]
E	B51ccc_B51x5	Smoking tobacco products [Exports]
E	B51ccc_B51x6	Smoking tobacco products [Imports]
E	B51cccc_B51x 1	Smoking tobacco products [Product]
++		

	B51cccc_B51x	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B51cccc_B51x 3	Smoking tobacco products [Domestic production]
	B51cccc_B51x 4	Smoking tobacco products [Retail sales]
	B51cccc_B51x 5	Smoking tobacco products [Exports]
	B51cccc_B51x 6	Smoking tobacco products [Imports]
	B51d_B51x1	Smokeless tobacco products [Product]
		Smokeless tobacco products
	B51d_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B51d_B51x3	kg Smokeless tobacco products [Domestic production]
	B51d_B51x4	Smokeless tobacco products [Retail sales]
	B51d_B51x5	Smokeless tobacco products [Exports]
	B51d_B51x6	Smokeless tobacco products [Imports]
		226,809
	B51e_B51x1	Smokeless tobacco products [Product]
	B51e_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B51e_B51x3	Smokeless tobacco products [Domestic production]
	B51e_B51x4	Smokeless tobacco products [Retail sales]
	B51e_B51x5	Smokeless tobacco products [Exports]
	B51e_B51x6	Smokeless tobacco products [Imports]
	B51f_B51x1	Smokeless tobacco products [Product]
	B51f_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]

B51f_	_B51x3 S r	nokeless tobacco products [Domestic production]
B51f_	_B51x4 S r	nokeless tobacco products [Retail sales]
B51f_	_B51x5 S r	nokeless tobacco products [Exports]
B51f_	_B51x6 S r	nokeless tobacco products [Imports]
B51ff_	_B51x1 S r	nokeless tobacco products [Product]
B51ff_	_B51x2 S r	nokeless tobacco products [Unit (e.g. pieces, tonnes)]
B51ff_	_B51x3 S r	nokeless tobacco products [Domestic production]
B51ff_	_B51x4 S n	nokeless tobacco products [Retail sales]
B51ff_	_B51x5 S n	nokeless tobacco products [Exports]
B51ff_	_B51x6 S n	nokeless tobacco products [Imports]
B51fff	_B51x1 S n	nokeless tobacco products [Product]
B51fff	_B51x2 S r	nokeless tobacco products [Unit (e.g. pieces, tonnes)]
B51fff	_B51x3 S n	nokeless tobacco products [Domestic production]
B51fff	_B51x4 S n	nokeless tobacco products [Retail sales]
B51fff	_B51x5 S n	nokeless tobacco products [Exports]
B51fff	_B51x6 S r	nokeless tobacco products [Imports]
B51ffff	_B51x1 S n	nokeless tobacco products [Product]
B51ffff	_B51x2 S n	nokeless tobacco products [Unit (e.g. pieces, tonnes)]
B51ffff	_B51x3 S r	nokeless tobacco products [Domestic production]
├		

B	51ffff_B51x4	Smokeless tobacco products [Retail sales]
B5	51ffff_B51x5	Smokeless tobacco products [Exports]
B5	51ffff_B51x6	Smokeless tobacco products [Imports]
В	851g_B51x1	Other tobacco products [Product]
В	851g_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
В	351g_B51x3	Other tobacco products [Domestic production]
В	351g_B51x4	Other tobacco products [Retail sales]
В	351g_B51x5	Other tobacco products [Exports]
В	851g_B51x6	Other tobacco products [Imports]
В	851h_B51x1	Other tobacco products [Product]
В	851h_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
В	851h_B51x3	Other tobacco products [Domestic production]
В	851h_B51x4	Other tobacco products [Retail sales]
В	851h_B51x5	Other tobacco products [Exports]
В	851h_B51x6	Other tobacco products [Imports]
В	351i_B51x1	Other tobacco products [Product]
В	351i_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
B	351i_B51x3	Other tobacco products [Domestic production]
В	351i_B51x4	Other tobacco products [Retail sales]
<u>├</u>		

, ,		les se se se
	B51i_B51x5	Other tobacco products [Exports]
	B51i_B51x6	Other tobacco products [Imports]
	B51ii_B51x1	Other tobacco products [Product]
	B51ii_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B51ii_B51x3	Other tobacco products [Domestic production]
	B51ii_B51x4	Other tobacco products [Retail sales]
	B51ii_B51x5	Other tobacco products [Exports]
	B51ii_B51x6	Other tobacco products [Imports]
	B51iii_B51x1	Other tobacco products [Product]
	B51iii_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B51iii_B51x3	Other tobacco products [Domestic production]
	B51iii_B51x4	Other tobacco products [Retail sales]
	B51iii_B51x5	Other tobacco products [Exports]
	B51iii_B51x6	Other tobacco products [Imports]
	B51iiii_B51x1	Other tobacco products [Product]
	B51iiii_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B51iiii_B51x3	Other tobacco products [Domestic production]
	B51iiii_B51x4	Other tobacco products [Retail sales]
	B51iiii_B51x5	Other tobacco products [Exports]

	B51iiii_B51x6	Other tobacco products [Imports]
	B51j_B51x1	Tobacco leaves [Product]
	B51j_B51x2	Tobacco leaves [Unit (e.g. pieces, tonnes)]
	B51j_B51x3	Tobacco leaves [Domestic production]
	B51j_B51x4	Tobacco leaves [Retail sales]
	B51j_B51x5	Tobacco leaves [Exports]
	B51j_B51x6	Tobacco leaves [Imports]
B52		Please provide information on the volumes of duty-free sales (e.g. product, unit, quantity), if available.
DEGA		Not available
B53A		Please indicate the year of the data used to answer question B51 and 52:
		2021
B53B		Please indicate the source of the data used to answer questions B51 and B52:
		Tobacco Reporting Regulations, Section 13 (Sales), Health Canada
B6		Seizures of illicit tobacco products (with reference to Article 15.5)
B61a_B61x1		Seizures of illicit tobacco
	B61a_B61x1	Smoking tobacco products [Year]
		Please see Annex 1
	B61a_B61x2	Smoking tobacco products [Product]
	B61a_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B61a_B61x4	Smoking tobacco products [Quantity seized]
	B61b_B61x1	Smoking tobacco products [Year]
	B61b_B61x2	Smoking tobacco products [Product]
	B61b_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]

B61b	o_B61x4	Smoking tobacco products [Quantity seized]
B61c	c_B61x1	Smoking tobacco products [Year]
B61c	c_B61x2	Smoking tobacco products [Product]
B61c	c_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
B61c	c_B61x4	Smoking tobacco products [Quantity seized]
B61c	c_B61x1	Smoking tobacco products [Year]
B61c	c_B61x2	Smoking tobacco products [Product]
B61c	c_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
B61c	c_B61x4	Smoking tobacco products [Quantity seized]
B61cc	cc_B61x1	Smoking tobacco products [Year]
B61cc	c_B61x2	Smoking tobacco products [Product]
B61cc	cc_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
B61cc	cc_B61x4	Smoking tobacco products [Quantity seized]
B61cc	ccc_B61x 1	Smoking tobacco products [Year]
B61cc	ccc_B61x 2	Smoking tobacco products [Product]
B61cc	ccc_B61x 3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
B61cc	ccc_B61x 4	Smoking tobacco products [Quantity seized]
	cccc_B61 x1	Smoking tobacco products [Year]
	cccc_B61 x2	Smoking tobacco products [Product]

B61ccccc_B61 x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
B61ccccc_B61 x4	Smoking tobacco products [Quantity seized]
B61ccccc_B6 1x1	Smoking tobacco products [Year]
B61cccccc_B6 1x2	Smoking tobacco products [Product]
B61cccccc_B6 1x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
B61cccccc_B6 1x4	Smoking tobacco products [Quantity seized]
B61d_B61x1	Smokeless tobacco products [Year]
B61d_B61x2	Smokeless tobacco products [Product]
B61d_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61d_B61x4	Smokeless tobacco products [Quantity seized]
B61e_B61x1	Smokeless tobacco products [Year]
B61e_B61x2	Smokeless tobacco products [Product]
B61e_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61e_B61x4	Smokeless tobacco products [Quantity seized]
B61f_B61x1	Smokeless tobacco products [Year]
B61f_B61x2	Smokeless tobacco products [Product]
B61f_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61f_B61x4	Smokeless tobacco products [Quantity seized]
B61ff_B61x1	Smokeless tobacco products [Year]
<u>├</u>	

B61	ff_B61x2	Smokeless tobacco products [Product]
	" DC1 -	
B61	ff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61	ff_B61x4	Smokeless tobacco products [Quantity seized]
B611	fff_B61x1	Smokeless tobacco products [Year]
B61	fff_B61x2	Smokeless tobacco products [Product]
B61	fff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61	fff_B61x4	Smokeless tobacco products [Quantity seized]
B61f	fff_B61x1	Smokeless tobacco products [Year]
B61f	fff_B61x2	Smokeless tobacco products [Product]
B61f	fff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61f	fff_B61x4	Smokeless tobacco products [Quantity seized]
B61f	ffff_B61x1	Smokeless tobacco products [Year]
B61f	ffff_B61x2	Smokeless tobacco products [Product]
B61f	ffff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61f	ffff_B61x4	Smokeless tobacco products [Quantity seized]
B61ff	ffff_B61x1	Smokeless tobacco products [Year]
B61ff	ffff_B61x2	Smokeless tobacco products [Product]
B61ff	ffff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61ff	ffff_B61x4	Smokeless tobacco products [Quantity seized]

	B61g_B61x1	Other tobacco products [Year]
	B61g_B61x2	Other tobacco products [Product]
	B61g_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61g_B61x4	Other tobacco products [Quantity seized]
	B61h_B61x1	Other tobacco products [Year]
	B61h_B61x2	Other tobacco products [Product]
	B61h_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61h_B61x4	Other tobacco products [Quantity seized]
	B61i_B61x1	Other tobacco products [Year]
	B61i_B61x2	Other tobacco products [Product]
	B61i_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61i_B61x4	Other tobacco products [Quantity seized]
	B61ii_B61x1	Other tobacco products [Year]
	B61ii_B61x2	Other tobacco products [Product]
	B61ii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61ii_B61x4	Other tobacco products [Quantity seized]
	B61iii_B61x1	Other tobacco products [Year]
	B61iii_B61x2	Other tobacco products [Product]
	B61iii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]

	B61iii_B61x4	Other tobacco products [Quantity seized]
	B61iiii_B61x1	Other tobacco products [Year]
	B61iiii_B61x2	Other tobacco products [Product]
	B61iiii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61iiii_B61x4	Other tobacco products [Quantity seized]
	B61iiiii_B61x1	Other tobacco products [Year]
	B61iiiii_B61x2	Other tobacco products [Product]
	B61iiiii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61iiiii_B61x4	Other tobacco products [Quantity seized]
	B61iiiii_B61x1	Other tobacco products [Year]
	B61iiiii_B61x2	Other tobacco products [Product]
	B61iiiii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61iiiii_B61x4	Other tobacco products [Quantity seized]
B62		Do you have any information on the percentage of illicit tobacco products on the national tobacco market?
		No
B63		What percentage of the national tobacco market do illicit tobacco products constitute? (%)
B64		What is the trend over the past two years or since submission of your last report in the percentage of illicit tobacco products in relation to the national tobacco market?
B65		Please provide any further information on illicit tobacco products. The Canada Border Services Agency (CBSA) and the Royal Canadian Mounted Police (RCMP)
		have shared responsibility for the surveillance, monitoring and enforcement of illicit tobacco activity along Canada's border and between ports of entry. The CBSA exercises its responsibilities at all ports of entry across Canada, while the RCMP is responsible for illicit tobacco activity between the ports of entry and domestically.
B66		Please indicate the source of the data used to answer questions in section B6:

B7		Tobacco-growing
D1		
B71		Is there any tobacco-growing in your jurisdiction?
		Yes
B72		Please provide information on the number of workers involved in tobacco-growing. If available, please provide this figure broken down by gender.
		Statistics Canada does not collect information specifically on the number of workers involved in tobacco-growing. Statistics Canada Census of Agriculture data indicates the number of tobacco farms in Canada in 2022 was 127, down from 195 in 2016. All of these farms were in the province of Ontario. This represents a decrease of 35% from 2016 to 2021. Tobacco farms represented 0.07% of the 189,874 total farms in Canada in 2021. On January 1, 2015, the Ontario Ministry of Finance began its oversight of the raw leaf tobacco industry. In June 2022 they reported 156 licensed growers of tobacco in Ontario, down from 200 reported in 2019. This represents a 22% decrease since 2019.
B73		Please provide, if available, the share of the value of tobacco leaf production in the nationa gross domestic product.
		The most recent data for the value of tobacco production is from 2019. According to the Ontario Ministry of Agriculture, Food and Rural Affairs, the total value of tobacco production in Ontario in 2019 was \$101,098,000. This represents 0.05% of Canada's GDP of \$CDN 2,007,421 million in 2019.
B74A		Please indicate the year of the data used to answer questions in section B7:
		2022
B74B		Please indicate the source of the data used to answer questions in section B7:
		Statistics Canada. Table 32-10-0166-01 Farms classified by farm type, Census of Agriculture historical data Ontario Ministry of Finance Raw leaf tobacco regulation ontario.ca Data for the value of tobacco provided by the Ontario Ministry of Agriculture, Food and Rural Affairs via email. Gross domestic product (GDP) at basic prices, by industry, monthly, growth rates (statcan.gc.ca)
B8		Taxation of tobacco products (with reference to Articles 6.2(a) and 6.3)
B81		What proportion of the retail price of the most popular price category of tobacco product consists of taxes (e.g. sum of excise, sales and import duties (if applicable) and value adde tax/goods and services tax (VAT/GST))?
		Prince Edward Island (PEI) - Assumed \$15 / 20 cigarette pack \$1.96 – HST \$5.90 – PTT \$3.17 – Fed. Excise \$11.03 – Total Tax \$11.03/\$15 = 73.5 %; BC - 32.5 cents per cigarette tobacco tax plus 7% PST on retail price; Manitoba (MB) - It's estimated that all provincial and federal taxes represent 70%; Saskatchewan (SK) - 71% of an average package; Quebec (QC) - Taxe d'accise fédérale (29.8 \$) Taxe spécifique provinciale (37.80 \$) Taxe de vente fédérale TPS (5 %). Pas de TVQ sur le tabac.; ON - Refer to response in B83 below as for some tobacco products such as cigarettes it is based on units whereas others like cigars it is based on the taxable price calculatior outlined in response B83.' Newfoundland and Labrador (NL) - Proportion of tax (federal excise, provincial tobacco tax and sales tax) to sale price is approximately 64% to 75%. Proportion varies based on retail price of cigarettes.; Alberta (AB) - With an average of 94% of all tobacco sales, cigarettes are the most popular product in the category. Alberta's tax on cigarettes is a per cigarette rate of 27.5 cents, which has declined from 50% to 40% in the last five years.; New Brunswick (NB) – Provincial taxes: Provincial tobacco tax of 25.52 cents per cigarette (\$6.38 in provincial tobacco tax per package of 25 cigarettes), plus 15% Harmonized Sales Tax (HST – 5% federal GST + 10% provincial portion).; Canada - Cigarettes – 63.33% of the final retail price consists of taxes.
SQ001		How are the excise taxes levied (what types of taxes are levied)?
	SQ001	Specific tax only
		Νο

	SQ002	Ad valorem tax only
		No
	SQ003	Combination of specific and ad valorem taxes
		Yes
	SQ004	More complex structure (please explain below)
		Yes
B82a		If a more complex structure of taxes (please explain):
		PEI - Specific taxes on cigarettes and loose tobacco – Both Fed. Excise tax and Provincial tobacco tax (\$/cigarette and \$/ gram). Specific tax on cigars under the Fed. excise tax. Ad valorem tax on cigars under the Provincial tax – 75% of MSRP QC - Pour les cigarettes ? Taxe d'accise fédérale (29.8 \$) Taxe spécifique provinciale (37.80 \$) Taxe de vente fédérale TPS (5 %). Pas de TVQ sur le tabac. Pour les cigares ? Taxe ad valorem sur le 80 % du prix taxable des cigares. Infos détaillées ? http://www.finances.gouv.qc.ca/documents/Bulletins/fr/BULFR_2023-2-f-b.pdf SK - This exception applies to cigars in Saskatchewan, where the tax is calculated based on taxable value with minimum and maximum thresholds. NB – Cigarette/Tobacco Stick/Other Tobacco: Provincial tobacco tax of 25.52 cents per cigarette/stick/gram plus 15% HST VAT. Cigars: 75% of suggested retail selling price plus 15% HST VAT. Canada – Tobacco products are taxed by both federal and provincial/territorial governments in Canada. For tobacco products are taxies publies: Federal excise duty, provincial tobacco tax of ST/HST) and, where applicable, provincial sales taxes. Federal Excise Duties: Federal excise duties are applied on all tobacco products. Provincial/territorial tobacco tax as: Provincial/territorial tobacco tax applies to tobacco products which are sold in that particular jurisdiction. Value Added Tax: The federal GST is levied on an ad valorem basis on most goods and services across Canada at the rate of 5%. Where a provincial GST/HST is levied on an ad valorem basis on most goods and services (including tobacco products) in that jurisdiction. Retail Sales Tax: A province/territory that has not harmonized with the federal value-added tax system may impose a retail sales tax on goods and services sold within its jurisdiction. Please see information provided under section B87B, including information on Canada's Goods and Services Tax (GST) and Harmonized Sales Tax (HST)
B83a_B83x1		If available, please provide details on the rates of taxation for tobacco products at all levels of Government and be as specific as possible (specify the type of tax, e.g. VAT, sales, import duties)
	B83a_B83x1	Smoking tobacco products [Product]
		Please see Annex 2
	B83a_B83x2	Smoking tobacco products [Type of tax]
	B83a_B83x3	Smoking tobacco products [Rate or amount]
	B83a_B83x4	Smoking tobacco products [Base of tax5]
	B83b_B83x1	Smoking tobacco products [Product]
	B83b_B83x2	Smoking tobacco products [Type of tax]
	B83b_B83x3	Smoking tobacco products [Rate or amount]
	B83b_B83x4	Smoking tobacco products [Base of tax5]

	B83c_B83x1	Smoking tobacco products [Product]
	B83c_B83x2	Smoking tobacco products [Type of tax]
	B83c_B83x3	Smoking tobacco products [Rate or amount]
	B83c_B83x4	Smoking tobacco products [Base of tax5]
	B83cc_B83x1	Smoking tobacco products [Product]
	B83cc_B83x2	Smoking tobacco products [Type of tax]
	B83cc_B83x3	Smoking tobacco products [Rate or amount]
	B83cc_B83x4	Smoking tobacco products [Base of tax5]
	B83ccc_B83x1	Smoking tobacco products [Product]
	B83ccc_B83x2	Smoking tobacco products [Type of tax]
	B83ccc_B83x3	Smoking tobacco products [Rate or amount]
	B83ccc_B83x4	Smoking tobacco products [Base of tax5]
	B83cccc_B83x 1	Smoking tobacco products [Product]
	B83cccc_B83x 2	Smoking tobacco products [Type of tax]
	B83cccc_B83x 3	Smoking tobacco products [Rate or amount]
	B83cccc_B83x 4	Smoking tobacco products [Base of tax5]
	B83ccccc_B83 x1	Smoking tobacco products [Product]
	B83ccccc_B83 x2	Smoking tobacco products [Type of tax]
	B83ccccc_B83	Smoking tobacco products [Rate or amount]

x3	
B83ccccc_B83 x4	Smoking tobacco products [Base of tax5]
B83cccccc_B8 3x1	Smoking tobacco products [Product]
B83cccccc_B8 3x2	Smoking tobacco products [Type of tax]
B83cccccc_B8 3x3	Smoking tobacco products [Rate or amount]
B83cccccc_B8 3x4	Smoking tobacco products [Base of tax5]
B83d_B83x1	Smokeless tobacco products [Product]
B83d_B83x2	Smokeless tobacco products [Type of tax]
B83d_B83x3	Smokeless tobacco products [Rate or amount]
B83d_B83x4	Smokeless tobacco products [Base of tax5]
B83e_B83x1	Smokeless tobacco products [Product]
B83e_B83x2	Smokeless tobacco products [Type of tax]
B83e_B83x3	Smokeless tobacco products [Rate or amount]
B83e_B83x4	Smokeless tobacco products [Base of tax5]
B83f_B83x1	Smokeless tobacco products [Product]
B83f_B83x2	Smokeless tobacco products [Type of tax]
B83f_B83x3	Smokeless tobacco products [Rate or amount]
B83f_B83x4	Smokeless tobacco products [Base of tax5]
B83ff_B83x1	Smokeless tobacco products [Product]
B83ff_B83x2	Smokeless tobacco products [Type of tax]

B83ff_B8	3x3 Smokeless tobacco products [Rate or amount]
B83ff_B8	3x4 Smokeless tobacco products [Base of tax5]
B83fff_B8	3x1 Smokeless tobacco products [Product]
B83fff_B8	3x2 Smokeless tobacco products [Type of tax]
B83fff_B8	3x3 Smokeless tobacco products [Rate or amount]
B83fff_B8	33x4 Smokeless tobacco products [Base of tax5]
B83ffff_B8	33x1 Smokeless tobacco products [Product]
B83ffff_B8	33x2 Smokeless tobacco products [Type of tax]
B83ffff_B8	33x3 Smokeless tobacco products [Rate or amount]
B83ffff_B8	33x4 Smokeless tobacco products [Base of tax5]
B83fffff_B8	83x1 Smokeless tobacco products [Product]
B83fffff_B8	83x2 Smokeless tobacco products [Type of tax]
B83fffff_B8	83x3 Smokeless tobacco products [Rate or amount]
B83fffff_B8	83x4 Smokeless tobacco products [Base of tax5]
B83ffffff_B	83x1 Smokeless tobacco products [Product]
B83ffffff_B	83x2 Smokeless tobacco products [Type of tax]
B83fffff_B	83x3 Smokeless tobacco products [Rate or amount]
B83ffffff_B	83x4 Smokeless tobacco products [Base of tax5]
	3x1 Other tobacco products [Product]

B83g_	_B83x2 Other	tobacco products [Type of tax]
B83g_	_B83x3 Other	tobacco products [Rate or amount]
B83g_	_B83x4 Other	tobacco products [Base of tax5]
B83h_	_B83x1 Other	tobacco products [Product]
B83h_	_B83x2 Other	tobacco products [Type of tax]
B83h_	_B83x3 Other	tobacco products [Rate or amount]
B83h_	_B83x4 Other	tobacco products [Base of tax5]
B83i_	B83x1 Other	tobacco products [Product]
B83i_	B83x2 Other	tobacco products [Type of tax]
B83i_	B83x3 Other	tobacco products [Rate or amount]
B83i_	B83x4 Other	tobacco products [Base of tax5]
B83ii_	_B83x1 Other	tobacco products [Product]
B83ii_	_B83x2 Other	tobacco products [Type of tax]
B83ii_	_B83x3 Other	tobacco products [Rate or amount]
B83ii_	_B83x4 Other	tobacco products [Base of tax5]
B83iii_	_B83x1 Other	tobacco products [Product]
B83iii_	_B83x2 Other	tobacco products [Type of tax]
B83iii_	_B83x3 Other	tobacco products [Rate or amount]
B83iii_	_B83x4 Other	tobacco products [Base of tax5]

	B83iiii_B83x1	Other tobacco products [Product]
	B83iiii_B83x2	Other tobacco products [Type of tax]
	B83iiii_B83x3	Other tobacco products [Rate or amount]
	B83iiii_B83x4	Other tobacco products [Base of tax5]
	B83iiiii_B83x1	Other tobacco products [Product]
	B83iiiii_B83x2	Other tobacco products [Type of tax]
	B83iiiii_B83x3	Other tobacco products [Rate or amount]
	B83iiiii_B83x4	Other tobacco products [Base of tax5]
	B83iiiiii_B83x1	Other tobacco products [Product]
	B83iiiii_B83x2	Other tobacco products [Type of tax]
	B83iiiii_B83x3	Other tobacco products [Rate or amount]
	B83iiiiii_B83x4	Other tobacco products [Base of tax5]
B84		 Please briefly describe the trends in taxation for tobacco products in the past two years or since submission of your last report in your jurisdiction. PEI - For PTT, there have been periodic increases (i.e. 2020 and 2022) BC - Effective July 1, 2022, PST was applied at the rate of 7% on tobacco sold in B.C AB - Smokeless tobacco fell under loose tobacco products until Alberta began taxing it separately in Spring 2022. Tobacco revenue has declined in the past two years. The 12-month period starting October shows a 16.5% reduction in overall tobacco tax revenue compared to the prior year. MB -No change in provincial tax rates. SK - Expansion of the tax base to include Heated Tobacco Products, increase in tax rates for all except cigars ON – No change to provincial tobacco tax rates as of January 31, 2023. The current provincial tobacco tax rates outlined in the chart response in B83 above have been in place since March 29, 2018. NB – The provincial tobacco tax rate was last changed (increased) on February 1, 2017. The provincial portion of the HST rate was last changed (increased) on July 1, 2016. Canada - Federal excise duty rates for tobacco products increased on April 1, 2020; April 1, 2021; April 20, 2021; and April 1, 2022 (rates available in Excise Duty Notice 73 and EDRATES on the CRA website). As such, since the beginning of the reporting cycle, in addition to the April 20, 2021 increase, three annual inflationary adjustments (i.e., April 2020, April 2021 and April 2022) have been applied to those duty rates. Federal excise duty rates on most tobacco products will be adjusted to so.62104 on April 1, 2020 and \$0.62725 on April 1, 2021 for inflation. This rate was then increased to \$0.72725 on April 20, 2021. The most recent inflationary adjustment happened on April 1, 2022 where the rate is now \$0.74470. This rate is set to be adjusted for inflation again

		on April 1, 2023. Provincial / Territorial Tobacco Tax rates increased in several jurisdictions; others remained at existing rates. One jurisdiction has recently imposed Provincial Sales Tax (PST) on previously-exempted sales of tobacco products. Rates of GST and HST were unchanged.
B85		Do you earmark any percentage of your taxation income for funding any national plan or strategy on tobacco control in your jurisdiction?
		No
B86		Please provide details in the space below.
B87A		Please indicate the year of the data used to answer questions B81 to B86:
		2023
B87B		Please indicate the source of the data used to answer questions B81 to B86:
		Federal/Provincial/Territorial Statutes and Regulations and other information are available on each governments website. Sources are as follows: PEI Tobacco Tax Act: https://www.princeedwardisland.ca/sites/default/files/legislation/t-03_11_0-tobacco_tax_act.pdf Alberta's Tax Revenue Administration, Monthly Tobacco Product Assessment, Alberta's Tobacco Tax Act, and Statistics Canada Saskatchewan Tax Act, 1998 https://www.ontario.ca/document/tobacco-tax MB - The Retail Tax Act (Manitoba), The Excise Tax Act (Canada), Physicians for a Smoke-Free Canada (for average price of a package of cigarettes), NB – NB Finance and Treasury Board Canada: Calculation done by Health Canada using data from the following sources: • Tobacco Reporting: As at December 31, 2022: Federal/Provincial/Territorial Statutes, Regulations, Section 13 (Sales), Health Canada • Tobacco Cigarettes, National & Regional C&G Banners, AC Nielsen Canada Federal and provincial other information available on government websites for excise and sales tax rates in Canada. Tobacco products are taxed by federal rates and provincial/territorial governments in Canada. At the federal level, the Excise Act, 2001 imposes excise duty on tobacco products manufactured in Canada at the time of packaging by the manufacturer and on imported tobacco taxes are consumption atxais imposed on consumers who purchase tobacco products. Provinces/territories secure their ta base by requiring wholesalers to remit an amount equal to the tax when they supply tobacco products are sold. The final consumer/retail sales price of tobacco products destined for ale for ale cice duty, provincial tobacco taxes are solg motile tobacco taxes are solg by provincial tobacco taxes are applied on all tobacco products. Provincial/Territorial Tobacco products retained for sale in that particular jurisdiction. Rates are applied on all tobacco products destined for sale in that particular jurisdiction. Rates are applied on all tobacco products destined for sale in that particular jurisdiction. Rates
B9		Price of tobacco products (with reference to Articles 6.2(a))
1_SQ001		Domestic Please provide the retail prices of the three most widely sold brands of domestic tobacco products at the most widely used point of sale in your capital city.
	1_SQ001	Smoking tobacco products [Name of the most widely sold brand]
		Next Original KS
	1_SQ002	Smoking tobacco products [Number of units or amount per package]
		25 units
	1_SQ003	Smoking tobacco products [Retail price]
	1	\$13.70

	1_SQ004	Smoking tobacco products [Currency]
		CAD
	2_SQ001	Smoking tobacco products [Name of the most widely sold brand]
		Belmont KS
	2_SQ002	Smoking tobacco products [Number of units or amount per package]
	_	25 units
	2_SQ003	Smoking tobacco products [Retail price]
	_	\$16.40
	2_SQ004	Smoking tobacco products [Currency]
	_	CAD
	3_SQ001	Smoking tobacco products [Name of the most widely sold brand]
	_	Next Xtra KS
++	3_SQ002	Smoking tobacco products [Number of units or amount per package]
		25 units
	3_SQ003	Smoking tobacco products [Retail price]
		\$13.64
	3_SQ004	Smoking tobacco products [Currency]
	0_04001	CAD
	7_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
		······································
	7_SQ002	Smokeless tobacco products [Number of units or amount per package]
	7_SQ003	Smokeless tobacco products [Retail price]
	7_SQ004	Smokeless tobacco products [Currency]
	_	
	8_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
	_	
+	8_SQ002	Smokeless tobacco products [Number of units or amount per package]
+	8_SQ003	Smokeless tobacco products [Retail price]
	8_SQ004	Smokeless tobacco products [Currency]
+	9_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
++	9_SQ002	Smokeless tobacco products [Number of units or amount per package]
		· · · · · · · · · · · · · · · · · · ·

	9_SQ003	Smokeless tobacco products [Retail price]
	9_SQ004	Smokeless tobacco products [Currency]
	13_SQ001	Other tobacco products [Name of the most widely sold brand]
	13_SQ002	Other tobacco products [Number of units or amount per package]
	13_SQ003	Other tobacco products [Retail price]
	13_SQ004	Other tobacco products [Currency]
	14_SQ001	Other tobacco products [Name of the most widely sold brand]
	14_SQ002	Other tobacco products [Number of units or amount per package]
	14_SQ003	Other tobacco products [Retail price]
	14_SQ004	Other tobacco products [Currency]
	15_SQ001	Other tobacco products [Name of the most widely sold brand]
	15_SQ002	Other tobacco products [Number of units or amount per package]
	15_SQ003	Other tobacco products [Retail price]
	15_SQ004	Other tobacco products [Currency]
1_SQ001		Imported Please provide the retail prices of the three most widely sold brands of imported tobacco products at the most widely used point of sale in your capital city.
	1_SQ001	Smoking tobacco products [Name of the most widely sold brand]
		John Player Rich
	1_SQ002	Smoking tobacco products [Number of units or amount per package]
		25 units
	1_SQ003	Smoking tobacco products [Retail price]
	<u> </u>	\$13.95
	1_SQ004	Smoking tobacco products [Currency]
		CAD

 2_SQ001	Smoking tobacco products [Name of the most widely sold brand]
	duMaurier Signature
2_SQ002	Smoking tobacco products [Number of units or amount per package]
	25 units
2_SQ003	Smoking tobacco products [Retail price]
	\$15.61
2_SQ004	Smoking tobacco products [Currency]
	CAD
3_SQ001	Smoking tobacco products [Name of the most widely sold brand]
	Pall Mall Smooth KS
3_SQ002	Smoking tobacco products [Number of units or amount per package]
	25 units
3_SQ003	Smoking tobacco products [Retail price]
	\$13.60
3_SQ004	Smoking tobacco products [Currency]
	CAD
7_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
	Copenhagen Snuff
7_SQ002	Smokeless tobacco products [Number of units or amount per package]
	34g
7_SQ003	Smokeless tobacco products [Retail price]
	\$25.21
7_SQ004	Smokeless tobacco products [Currency]
	CAD
8_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
	Skoal Pouches Straight
8_SQ002	Smokeless tobacco products [Number of units or amount per package]
	23.25g
8_SQ003	Smokeless tobacco products [Retail price]
	\$21.85
8_SQ004	Smokeless tobacco products [Currency]
	CAD
9_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
	Skoal Straight
9_SQ002	Smokeless tobacco products [Number of units or amount per package]
	34g
9_SQ003	Smokeless tobacco products [Retail price]
	\$25.20
	\$25.20

I	9_SQ004	Smokeless tobacco products [Currency]
		CAD
	13_SQ001	Other tobacco products [Name of the most widely sold brand]
	13_SQ002	Other tobacco products [Number of units or amount per package]
	13_SQ003	Other tobacco products [Retail price]
	13_SQ004	Other tobacco products [Currency]
	14_SQ001	Other tobacco products [Name of the most widely sold brand]
	14_SQ002	Other tobacco products [Number of units or amount per package]
	14_SQ003	Other tobacco products [Retail price]
	14_SQ004	Other tobacco products [Currency]
	15_SQ001	Other tobacco products [Name of the most widely sold brand]
	15_SQ002	Other tobacco products [Number of units or amount per package]
	15_SQ003	Other tobacco products [Retail price]
	15_SQ004	Other tobacco products [Currency]
B92A		Please indicate the year of the data used to answer question B91:
		2021
B92B	1	Please indicate the source of the data used to answer question B91:
		Tobacco Reporting Regulations, Section 13 (Sales), Health Canada Tobacco Cigarettes, National & Regional C&G Banners, AC Nielsen Canada
B93		Please briefly describe the trend in the prices of tobacco products in the past two years or since submission of your last report in your jurisdiction.
		From 2019 to 2021, the average retail price for pack of cigarettes has increased by approximately 11%. Source: Tobacco Reporting Regulations, Section 13 (Sales), Health Canada Tobacco Cigarettes, National & Regional C&G Banners, AC Nielsen Canada

C1. GENERAL OBLIGATIONS

C1		With reference to Article 5
C111		Have you developed and implemented comprehensive multisectoral national tobacco control strategies, plans and programmes in accordance with the Convention?
		Yes
C112		Have you partially developed and implemented tobacco control strategies by including tobacco control in national health, public health or health promotion strategies, plans and programmes?
		N/A
C113		Is any aspect of tobacco control that is referred to in the Convention included in any national strategy, plan or programme?
		N/A
C114a		Have you established or reinforced and financed:
	C114a	a focal point for tobacco control?
		Yes
	C114b	a tobacco control unit?
		Yes
	C114c	a national coordinating mechanism for tobacco control?
		Yes
C115		Please provide details (e.g. the nature of the national coordinating mechanism, the institution to which the focal point for tobacco control or the tobacco control unit belongs).
		Health Canada, the federal department of Health, is the focal point for tobacco control in Canada and maintains a financed tobacco control unit. Each province and territory also has a respective focal point. Health Canada maintains national coordinating mechanisms with provinces and territories including through the federal/provincial/territorial Tobacco Control Liaison Committee. Health Canada also maintains coordinating mechanisms with non-government organizations, including through a quarterly NGO Forum. As part of Canada's Tobacco Strategy, the Government of Canada has committed to working with our partners by to: increase funding to study new and unique was to address tobacco use in Canada; aid research from health stakeholders by publicly releasing industry reports, research findings and surveillance findings; and working with national and regional Indigenous groups to co-develop distinct strategies to meet the needs of Canada's Indigenous peoples.
C116		Please provide a brief description of the progress made in implementing Article 5.1 and 5.2 (General obligations) in the past two years or since submission of your last report.
		Health Canada is reviewing Canada's Tobacco Strategy and exploring new opportunities to reduce tobacco consumption and achieve less than 5% by 2035. We continue to strengthen regulations to prevent youth and people who do not smoke from becoming addicted and to provide Canadians with information on the health hazards of tobacco use. In 2022, we published proposed regulations to update health warning messages and to extend to all tobacco product packages to maintain the effectiveness. Additionally, we have proposed regulations which would make Canada the first country to introduce written health warnings on certain individual tobacco products, such as cigarettes, to make it nearly impossible to avoid health warnings altogether. Health Canada recently completed the first legislative review of the Tobacco and Vaping Products Act, which determined that the Act is making progress towards protecting youth and achieving its vaping-related objectives. It also identified areas for potential action, such as strengthening our compliance and enforcement. Another review will begin in 2023. Finally, Health Canada is developing guidance on Article 5.3 which we will share across government departments in order to increase our compliance with Article 5.3.
C117		If you have any other relevant information pertaining to but not covered in this section,

C12	Protection of public health policies with respect to tobacco control from commercial and other vested interests of the tobacco industry Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C121	protecting public health policies with respect to tobacco control from commercial and othe vested interests of the tobacco industry?
	Yes
C122	ensuring that the public has access, in accordance with Article 12(c), to a wide range of information on tobacco industry activities relevant to the objectives of the Convention, suc as in a public repository?
	Yes
C123	If you answered "Yes" to any of the questions under C121 or C122, please provide details in the space below (specifically, please refer, if relevant, to whether your government or any or its departments 1) have raised awareness on tobacco industry tactics and the need to prevent interference by the tobacco industry with decision making; 2) have avoided enterin into any partnerships or voluntary agreements with the tobacco industry; 3) have established any measures to limit interaction of public officials with the tobacco industry, including in the form of a code of conduct; 4) have not granted any incentives, privileges, benefits or preferential tax exemptions to the tobacco industry to establish or run their business; etc.).
	PEI - The province of PEI has issued letters to the tobacco industry requesting that they stop all promotional tactics involving retailers promoting specific tobacco products to customers (e.g., mystery shoppers and gift cards provided to retailers if they promote their brand). The PEI Government has issued letters to tobacco retailers advising that participation in tobacco companie promotional tactics is against provincial law and they must stop. Although no formal code of conduct, public health officials leading tobacco control efforts including tobacco control policy development do not meet or engage with representatives from the tobacco industry BC – To align with Canada's adoption of the World Health Organization Framework Convention on Tobacco Control and to demonstrate transparency and openness, the Ministry maintains a record of meetings with tobacco and vapour product industry representatives. https://www2.gov.bc.ca/gov/c ntent/kealth/keeping-bc-healthy-safe/tobacco-vapour/meetings-with-tobacco-vapour-industry AB - Internal restrictions are present to prevent interactions with tobacco industry NL Follow Federal policy of not partnering with the tobacco information around smoking cessation/harm reduction through community partners - No preferential tax exemptions to the tobacco industry - Smoking cessation resources/services are based on evidence-based research and best practice Canada – Health Canada has committed to meeting with industry representatives only to the extent necessary to regulate the industry, and to exercise transparency with these meetings by preparing summaries and making them available on our website: https://www.canada.ca/en/health-canada/services/health-concerns/tobacco/meeting-summaries-tobacco-vaping-industry.html
C124	Please provide a brief description of the progress made in implementing Article 5.3 in the past two years or since submission of your last report.
	BC - Reviewed and familiarized myself with Article 5.3 AB - No changes made since Jan. 2020. Canada - Public Safety follows a strict procedure when interacting with the tobacco industry and it subsidiaries in order to protect GoC policy from their commercial interests. Public Safety has a standard verbal disclosure statement that it uses to inform tobacco industry representatives and their subsidiaries that information collected and provided during these interactions is subject to Access to Information Policy and full disclosure will be made.
C125	Have you utilized the "Guidelines for implementation of Article 5.3 of the WHO FCTC" when developing or implementing policies in this area?
	Yes
C126	Please provide details in the space below or refer to section I of the additional questionnaire. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/index.php/862235?token={TOKEN}⟨=0 n
	BC - Relying on Article 5.3 to develop a policy to deal with tobacco and vapour lobbyists NL – Wo with Community partners to raise awareness about the addictive and harmful nature of tobacco products The Smoke Free Environment Act (2005) - aims to protect the public from exposure to

	second-hand smoke - promotes the creation of healthy public environments - prohibits smoking in all indoor public places (including bars, decks and bingo halls), workplaces and in motor vehicles while persons under 16 years of age are present - prohibits the use of electronic cigarettes in indoor public places (restaurants, licensed liquor establishments), workplaces and in motor vehicles while persons under the age of 16 are present - prohibits designated smoking and designated e- cigarette rooms in workplaces (Smoke-free Environment Regulations) - prohibits hookah/water pipe smoking in indoor public places and workplaces
C127	If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
	PEI provides tobacco training to all tobacco retailers on the rules and regulations regarding the proper selling of tobacco products and how to comply with provincial legislation. Ontario's Lobbyist Registry enables the public to identify the individuals and firms representing the tobacco industry's perspective to government.

C2. MEASURES RELATING TO THE REDUCTION OF DEMAND FOR TOBACCO

C2	With reference to Articles 6–14
C21	Price and tax measures to reduce the demand for tobacco Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures o have you implemented, where appropriate, programmes on any of the following:
C211	tax policies and, where appropriate, price policies on tobacco products so as to contribute to the health objectives aimed at reducing tobacco consumption?
	Yes
C212	prohibiting or restricting, as appropriate, sales to international travellers of tax- and duty- free tobacco products?
	Yes
C213	prohibiting or restricting, as appropriate, imports by international travellers of tax- and dut free tobacco products?
	Yes
C214	Please provide a brief description of the progress made in implementing Article 6 (Price an tax measures to reduce the demand for tobacco) in the past two years or since submission of your last report.
C215	Have you utilized the "Guidelines for implementation of Article 6 of the WHO FCTC" when developing or implementing policies in this area?
	No
C216	If you answered "Yes" to question C215 please provide details in the space below or refer section H of the additional questionnaire available at this link. Response to this question of to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
C217	If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
	Canada - Article 6 of the WHO FCTC is not explicitly considered when shaping tobacco taxation policy. Certain guiding principles of Article 6 are part of tobacco tax policy (e.g., 1.3: Effective tobacco taxes are an important source of revenue; 1.5: Tobacco tax systems and administration should be efficient and effective). No new policies since the last report have been undertaken in line with Article 6 specifically. That said, as mentioned in C214, during the reporting cycle, there was a one-time increase in the federal tobacco excise duties on tobacco products on April 20, 2021, as well as annual inflationary adjustments on those duty rates in April 2020, April 2021 and April 2022. To provide greater certainty: with respect to questions C213 and C214, measures to deal with the sales to and imports by international travellers were put in place before the current reporting cycle (i.e., 2020-2023).
C22	Protection from exposure to tobacco smoke Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C221	- banning, completely or partially, tobacco smoking in indoor workplaces, public transport indoor public places and, as appropriate, other public places?
	Yes
1	What is the type/nature of the measure providing for the ban?

	1	national law
		Yes
	2	subnational law(s)
		Yes
	3	administrative and executive orders
		Yes
	4	voluntary agreements
		Yes
	5	other measures (please specify in C223 below)
		Yes
C223		Please provide a brief explanation of the type/nature and content of the measures providing for the ban.
		PEI – PEI's Smoke Free Places Act prohibits in public places (unless in a designated area) no smoking withing 4.5 meters of entrances, windows and air intakes. Act does not allow smoking in vehicles with people under the age of 19. Municipalities have by-laws and policies in place for no smoking on sports fields, recreation facilities, parks, etc. Voluntary agreements – properties may have a non-smoking policy or a lease agreement that further restricts smoking or vaping. Many buildings are bringing in smoke-free and vapour-free policies NB – The New Brunswick Smoke-Free Places Act applies to all enclosed public places, indoor workplaces, in a public vehicle and or school grounds. It also prohibits smoking in vehicles with passengers under age 16 years. "Public vehicle" means a motor vehicle or ferry that is used or made available for public transit or is used to transport members of the public, but only during any period that the vehicle is available for hire, including any break period. New Brunswick's legislation regarding smoke-free outdoor spaces has a far greater reach because it establishes larger smoke-free zones: 3m around patios, 9m around airways and doorways, etc. SFPA: http://laws.gnb.ca/en/ShowPdf/cs/2011-c.222.pdf
C224		Do any of these measures provide for a mechanism/ infrastructure for enforcement? Yes
C225		Please provide details of this system.
		PEI - PEI's Smoke Free Places Act issues summary offense fines in place of violations of the Act. BC - In cases where violations of the Tobacco and Vapour Products Control Act or Regulation are considered to have been made by retailers, the violation may be referred to either the provincial court system or to the Administrator of the Tobacco and Vapour Products Control Act for an administrative hearing. Penalties for contraventions under legislation vary, based on the violation type, retail history and by enforcement method and are done in conjunction with regional health authorities. AB - Supporting legislation details the fines and punishments associated with violations of tobacco use bans MB - The Smoking and Vapour Products Control Act includes sales to minors smoking in public places; and provisions restricting the display advertising and promotion of tobacco and vaping products. The Act is enforced by the Tobacco Officer in the department of Mental Health and Community Wellness through education, compliance checks and if required, warnings and charges. Drifting Smoke/vapour and smoking/vaping in public places is enforced by Public Health Officers in the department of Health. Warnings and charges are issued as required. SK - Provincial legislation provides fine amounts for non-compliance with tobacco/vapour product control requirements. Summary offence tickets can be issued by enforcement officials or greater fines levied by the court. ON - Ontario's Ministry of Health is responsible for the administration of the Smoke-Free Ontario Act, 2017 (SFOA, 2017) under sections 20 and 21, Ontario's local Boards of Health are responsible for the enforcement of the SFOA, 2017. Boards of Health's responsibilities include inspecting secondary schools (at least once per year) and responding to all complaints from the public. In fulfilling these requirements, Boards of Health are mandated by the ministry to use a compliance strategy that employs a balance of education, inspection and progressive enforcement. "Progressive
1		Please specify the settings and extent/comprehensiveness of measures applied in indoor workplaces, public transport, indoor public places and, as appropriate, other public places. Indoor workplaces:

	1	government buildings
	I	
		Complete
	2	health-care facilities
		Complete
	3	educational facilities6
		Complete
	4	universities
		Complete
	5	private workplaces
		Complete
	6	other (please specify below)
		Partial
C226aa		Please provide a brief explanation of any "other" policies in the space below
1		https://www2.gov.bc.ca/gov/content/health/keeping-bc-healthy-safe/tobacco-vapour/requirements- under-tobacco-vapour-product-control-act-regulation/tobacco-vapour-free-places MB - • Smoking and vaping is banned in the following places in Manitoba: o An enclosed public place o An indoor workplace o A group living facility o A public vehicle o In a vehicle where a child under the age of 16 is present o On the beaches and playgrounds of provincial parks o On outdoor patios (Winnipeg only) • The City of Winnipeg By-law No. 62/2011 further bans smoking and vaping in the following places: o On an outdoor patio o Within 30 metres of the playing surface of an athletic field or a hockey rink during a youth event o On a playground o Within 30 metres of a swimming pool, wading pool, spray pad or spray park owned or operated by the City of Winnipeg o On the premises of a primary school, middle school or secondary school, whether a public school or a private school o On the premises of a health care facility o Within 8 metres from an outdoor entrance providing direct access to a City of Winnipeg workplace Within 8 metres from an outdoor entrance providing direct access to a WRHA workplace. cities of Thompson and Steinbach also have by-laws that place further restrictions on smoking. AB - Legislation increased scope of consumption ban on school properties, hospital properties and childcare properties. Post- secondary educational facilities are not explicitly included in the legislation. NB – Smoke-Free Places Act "enclosed public place" means all or any part of a building or other enclosed place, other than a group living facility, to which members of the public have access as of right or by express or implied invitation, and includes (a) the common areas of multiunit residential building, (b) an outdoor bus or taxi shelter, (c) an outdoor eating or drinking area referred to in subsection (2), (c.1) a place that is more than 70% enclosed by a wall or a roof or a combination of the two
1		workplaces, public transport, indoor public places and, as appropriate, other public places. Public transport:
	1	Complete
	2	trains
		Complete
	3	ferries
	č	
	4	Complete
	4	ground public transport (buses, trolleybuses, trams)
		Complete
	5	private vehicles

	Complete
6	other (please specify below)
	Complete
C226bb	Please provide a brief explanation of any "other" policies in the space below
C226bb	
	or (b) smoking is permitted on the aircraft only in designated smoking areas NL - The Smoke-Free Environment Act, 2005 prohibits smoking in enclosed public places (e.g., restaurants, bars
	including patio decks, bingo halls, ferries), workplaces and in motor vehicles when persons under the age of 16 are present in the vehicle. In June 2016, the Smoke-Free Environment, 2005 was amended: ? Prohibition on persons under the age of 19 from entering or working in a hookah

		tobacco shisha in indoor public places and work place, and in motor vehicles when occupied by a person under the age of 16 (came into force on June 7, 2016) ? Prohibition on hookah/water pipe smoking in indoor public places and workplaces including any existing hookah establishments (came into force on July 1, 2017). NB – The New Brunswick Smoke-Free Places Act prohibits smoking in vehicles with passengers under age 16 years.
1		Please specify the settings and extent/comprehensiveness of measures applied in indoor workplaces, public transport, indoor public places and, as appropriate, other public places. Indoor public places:
	1	cultural facilities
		Complete
	2	shopping malls
		Complete
	3	pubs and bars
		Complete
	4	nightclubs
		Complete
	5	restaurants
		Complete
	7	other (please specify below)
		Complete
C226cc		Please provide a brief explanation of any "other" policies in the space below
		PEI - Outdoor patios can be designated smoking areas from 10pm until 3am. BC - TOBACCO AND VAPOUR PRODUCTS CONTROL ACT allows cultural facilities, shopping malls, pubs and bars, nightclubs and restaurants to have a 6 metre buffer zone around all doorways, air intakes and open windows to any public and work places in B.C. MB - Exception for tobacconist shops 4 The proprietor of a tobacconist shop and his or her employees and customers may smoke tobacco in a tobacconist shop to test or sample a product if the shop (a) is fully enclosed by floor-to-ceiling walls, a ceiling and doors that separate it physically from any adjacent area in which smoking is prohibited by this Act; and (b) has a separate ventilation system if the shop is first opened for business after this section comes into force. Exception for vapour product shops 4.1 The proprietor of a vapour product shop and his or her employees and customers may use e-cigarettes in a vapour product shop to test or sample a product for the purpose of sale of the product for use elsewhere, but only if the shop is fully enclosed by floor-to-ceiling walls, a ceiling and doors that separate in which the use of e-cigarettes is prohibited. ON - SFOA, 2017 prohibits smoking in all indoor workplaces and public spaces. With minor exceptions described in C223.
C227		Please provide a brief summary of complete and partial measures, with specific details of the partial measures that have been implemented:
C227a		Banning tobacco smoking in indoor workplaces
		MB - No smoking in enclosed places 2(1) no person shall smoke in (a) an enclosed public place; (b) an indoor workplace; (c) a group living facility; (d) a public vehicle; or (e) a vehicle used in the course of employment, while carrying two or more employees. PEI – Yes BC - No tobacco or vapour product use in or near certain places TOBACCO AND VAPOUR PRODUCTS CONTROL ACT 2.3 (1)Subject to subsection (2), a person must not smoke tobacco, hold lighted tobacco, use an e-cigarette, or hold an activated e-cigarette: (a)in any building, structure, vehicle or any other place that is fully or substantially enclosed and (ii)is a workplace MB - "indoor workplace" means an enclosed area of a building, structure, mine or other premises in which an employee engages in work, including any eating area, washroom, corridor, lounge, reception area, lobby, elevator, escalator, stairway, amenity area, storage area, closet, laundry room and parking garage used by employees, and any other enclosed area frequented by employees during the course of their employment, but does not include a private residence; (« lieu de travail intérieur ») SK - Occupational Health and Safety legislation includes prohibitions on ON - SFOA, 2017 prohibits

	smoking in all indoor workplaces. and public spaces. With minor exceptions described in C223. NL – Complete for all workplaces
C227b	Banning tobacco smoking in public transport
	PEI – Yes BC - No Smoking on Transit Vehicles & in Bus Shelter. Provincial tobacco laws (The Tobacco Control Act) prohibit smoking in bus shelters, on transit vehicles at all times and within 3 metres (10 feet) of the bus. MB - "public vehicle" means a motor vehicle used for the public transportation of persons or property, and includes a bus, taxi or limousine; (« véhicule public ») SI - Tobacco control legislation prohibits smoking in public transportation. Private vehicles that are used for public transport, including taxis, are subject to legislation only when available for public service. ON - Complete prohibition NL - Complete for vehicles carrying passengers for hire
C227c	Banning tobacco smoking in indoor public places
	PEI – Yes BC - Smoking and vaping is not permitted in any fully or substantially enclosed public place or workplace, or in the buffer zone around doors, open windows and air intakes to these locations. This includes both permanent structures and temporary ones such as marquee tents. MI - "enclosed public place" means any part of an enclosed place to which members of the public have access, including, but not limited to, (a) any part of (i) an office building, (ii) a retail store or other commercial establishment, or (iii) the common areas of a residential building or shopping mall, (b) a health care facility, (c) a day care centre or nursery, (d) an educational institution or facility, (e) a restaurant, (f) an elevator, (g) a licensed premises, (h) an enclosed place, other than a private residence, in which a private function is being held, (i) a private club to which a member or invited person has access, (j) a bus shelter, pedestrian tunnel or enclosed pedestrian walkway, and (k) any other place or class of places prescribed by regulation; (« endroit public fermé ») SK - Provincial legislation prohibits the use of commercial tobacco in all enclosed public places. Specific exemptions for First Nation cultural ceremonies and ventilated smoking rooms for residents in designated long-term care facilities. ON - SFOA, 2017 prohibits smoking in all indoor workplaces and public spaces. With minor exceptions described in C223. NL - Complete for any place that is normally open to the public
C228	 Please provide a brief description of the progress made in implementing Article 8 (Protection from exposure to tobacco smoke) in the past two years or since submission of your last report. PEI - March 1, 2020: news tobacco and vaping laws came into force. Minimum age of purchases tobacco and nicotine vaping products increased from age 19 to 21 years. Nicotine vaping products are only available in stories designated as "tobacconist shops" – these stores are age -restricted, meaning that only people who are of legal age can purchase products can enter them. March 1, 2021: the sale of flavored vaping products (with the exception of tobacco flavor) is prohibited in
	PEI. BC - Banning smoking in bus shelters – in progress SK - Legislation was amended to include vaping restrictions.
C229	Have you utilized the "Guidelines for implementation of Article 8 of the WHO FCTC" when developing or implementing policies in this area?
	Yes
C2210	If you answered "Yes" to question C229 please provide details in the space below or refer to section B of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en ON - The Scope of Effective Legislation Ontario's legislation provides protection from secondhand smoke in all indoor or enclosed workplaces with minor exceptions described in C223. Inform, Consult and Involve the Public to Ensure Support and Smooth Implementation In implementing the establishment of smoke-free spaces through the SFOA, 2017, Ontario's Ministry of Health engages in public outreach and stakeholder consultations. Enforcement Ontario has a robust inspection system that included the elements of Article 8 including signage, regular inspections, penalties, and public access to a complaints process. Monitoring and Evaluation of Measures Ontario regularly monitors progress through a provincial database which records all inspections. In addition, a government agency, Public Health Ontario, is responsible for producing a monitoring report which offers a wider analysis. NL - The Smoke-Free Environment Act 2005 aims to protect the public from exposure to second-hand smoke and promotes the creation of healthy public environments
C2211	If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C23	Regulation of the contents of tobacco products Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you

		implemented, where appropriate, programmes on any of the following:
C231		testing and measuring the contents of tobacco products?
		Yes
C232		testing and measuring the emissions of tobacco products?
		Yes
C233		regulating the contents of tobacco products?
		Yes
C234		regulating the emissions of tobacco products?
		No
C235		Please provide a brief description of the progress made in implementing Article 9 (Regulation of the contents of tobacco products) in the past two years or since submission of your last report.
0000		
C236		Have you utilized the "Guidelines for implementation of Articles 9 and 10 of the WHO FCTC" when developing or implementing policies in this area?
		No
C237		If you answered "Yes" to question C236 please provide details in the space below or refer to section C of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
C238		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below (e.g., whether your country 1) has incorporated product regulation in the national tobacco control legislation; 2) has access to either governmental or independent – not owned or controlled by the tobacco industry – laboratories for testing contents and/or emissions of tobacco products; 3) has regulated ingredients, such as flavours (e.g. menthol); 4) has regulated product characteristics, such as design features (e.g., cigarette ventilation); etc.).
		Canada - We have access to independent laboratories. We have prohibited a large number of additives in cigarettes and other tobacco products, including menthol. We have regulated some product characteristics such as dimensions and appearance of cigarettes.
C24		Regulation of tobacco product disclosures Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
1		requiring manufacturers or importers of tobacco products to disclose to Government authorities information about the:
	1	contents of tobacco products?
	2	Yes
	2	emissions of tobacco products?
		Yes
1		requiring public disclosure of information about the:
	1	contents of tobacco products?

		No
	2	emissions of tobacco products?
		No
C243		Please provide a brief description of the progress made in implementing Article 10 (Regulation of tobacco product disclosures) in the past two years or since submission of your last report.
		NIL
C244		Have you utilized the "Guidelines for implementation of Articles 9 and 10 of the WHO FCTC" when developing or implementing policies in this area?
		No
C245		If you answered "Yes" to question C244 please provide details in the space below or refer to section C of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
C246		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below (e.g. whether your country has incorporated tobacco product disclosures in the national tobacco control legislation; has regulated the public disclosure of toxic constituents and emissions of tobacco products, aiming to raise public awareness and advance tobacco control policy; etc.).
C25		Packaging and labelling of tobacco products Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C251		requiring that packaging, individual cigarettes or other tobacco products do not carry advertising or promotion?
		Yes
C252		requiring that packaging and labelling do not promote a product by any means that are false, misleading, deceptive or likely to create an erroneous impression about its characteristics, health effects, hazards or emissions? Yes
C253		requiring that each unit packet and package of tobacco products and any outside packaging and labelling of such products carry health warnings describing the harmful effects of tobacco use? Yes
C254		ensuring that the health warnings are approved by the competent national authority?
		Yes
C255		ensuring that the health warnings are rotated?
		Yes
C256		ensuring that the health warnings are clear, visible and legible?
		Yes
C257		Does your law mandate, as a minimum, a style, size and colour of font to render the warning clear, visible and legible?
		Yes
C258		ensuring that the health warnings occupy no less than 30% of the principal display areas?
		Yes

C259		ensuring that the health warnings occupy 50% or more of the principal display areas?
		Yes
C2510		ensuring that health warnings are in the form of, or include, pictures or pictograms?
		Yes
C2511		Does the Government own the copyright to these pictures and pictograms?
		Yes
C2512		Would you grant a non-exclusive and royalty-free licence for the use of health warnings developed in your jurisdiction with other Parties?
		Yes
1		requiring that each unit packet and package of tobacco products and any outside packaging and labelling of such products contain information on relevant:
	1	constituents of tobacco products?
		Yes
	2	emissions of tobacco products?
		Yes
C2514		requiring that the warnings and other textual information appear on each unit packet and package and on any outside packaging and labelling in the principal language or languages of the country?
		Yes
C2515		Please provide a brief description of the progress made in implementing Article 11 (Packaging and labelling of tobacco products) in the past two years or since submission of your last report.
		NIL
C2516		Have you utilized the "Guidelines for implementation of Article 11 of the WHO FCTC" when developing or implementing policies in this area?
		No
C2517		If you answered "Yes" to question C2516 please provide details in the space below or refer to section D of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
C2518		If you have any other relevant information pertaining to or not covered in this section, please provide details in the space below.
		PEI's Tobacco and Electronic Smoking Device Sales and Access Act Section 5.4: false, deceptive, misleading advertising. PEI has charged retailers for carrying products in violation and have a conviction in court under this section.
C26		Education, communication, training and public awareness Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C261		educational and public awareness programmes? (Please refer to programmes implemented since submission of your two-year report.)
		Yes
1		To whom are these programmes targeted?

	1	adults or the general public
		Yes
	2	children and young people
		Yes
	3	men
		Yes
	4	women
		Yes
	5	pregnant women
		Yes
	6	ethnic groups
		Yes
	7	other
	-	Yes
C2621		Please specify
02021		Note: Vaping specific. HC selected adults or general public, men and women; PHAC selected
		children and young people, pregnant women, ethnic groups, and other. HC programming is vaping specific.; MB – The department's school-based Review and Rate program, where high students select the best international anti-tobacco and vaping TV ads, provides an opportunity for education on the harms associated with smoking and vaping, and the benefits of quitting. AB – GeminAl Rising – children/young people Social media campaigns – Smoking, vaping and COVID 19/Infectious Diseases; vaping – youth and parents What are the Odds? -Men's cessation campaign Other cessation campaigns – 'Reasons for Quitting', Fact or Fiction Tool NL – - Educational curriculum-based resources for students in Grades 7-12 in the NL English School district province wide regarding tobacco and vaping awareness - Resources available for all ages through the Smokers Helpline NL, provides telephone counseling, email/text messages with daily quit tips - Resources and information regarding tobacco, health risks and treatment/cessation options available on Bridgethegapp.ca for both adults and youth - Ottawa Model for Smoking Cessation (OMSC) implemented in 2 health facilities in the province QC – LGBT programming is vaping and an education and public awareness component are adapted for their particular target groups. See additional input document (Annex 3) for program and project descriptions. MB – The department's school-based Review and Rate program, where high students select the best international anti-tobacco and vaping TV ads, provides an opportunity for education on the harms associated with smoking and vaping, and the benefits of quitting. AB - GeminAI Rising – children/young people Social media campaigns – Resources available for all ages through the Smokers Helpline NL, provides telephone counseling, email/ext messages with daily quit tips - Resources and information regarding tobacco, health risks and treatment/cessation campaign Other cessation campaigns – 'Reasons for Quitting', Fact or Fiction Tool NL – - Educational curriculum-based r

		descriptions. MB – The department's school-based Review and Rate program, where high students select the best international anti-tobacco and vaping TV ads, provides an opportunity for education on the harms associated with smoking and vaping, and the benefits of quitting. AB - GeminAl Rising – children/young people Social media campaigns – Smoking, vaping and COVID 19/Infectious Diseases; vaping – youth and parents What are the Odds? -Men's cessation campaign Other cessation campaigns – 'Reasons for Quitting', Fact or Fiction Tool NL – - Educational curriculum-based resources for students in Grades 7-12 in the NL English School district province wide regarding tobacco and vaping awareness - Resources available for all ages through the Smokers Helpline NL, provides telephone counseling, email/text messages with daily quit tips - Resources and information regarding tobacco, health risks and treatment/cessation options available on Bridgethegapp.ca for both adults and youth - Ottawa Model for Smoking Cessation (OMSC) implemented in 2 health facilities in the province QC – LGBT programming Canada (PHAC): HCCF projects with an education and public awareness component are adapted for their particular target groups. See additional input document for program and project descriptions.
1		Do you reflect the following key differences among targeted population groups in educational and public awareness programmes?
	1	age Yes
	2	gender
	2	Yes
	3	educational background Yes
	4	cultural background
		Yes
	5	socioeconomic status Yes
	6	other
	Ŭ	
00004		Yes
C2631		Please specify MB - The department's school-based Review and Rate program, where high students select the best international anti-tobacco and vaping TV ads, provides an opportunity for education on the harms associated with smoking and vaping, and the benefits of quitting. AB - Social media campaigns translated into 5 languages Men's campaign focused on blue collar workers Keep Tobacco Sacred Collaborative – Indigenous youth and elders NL – - Resources provided specifically for youth including information on vaping through the school system and Bride the gApp youth section - "Helping Women Live Smoke-Free Initiative" supports Family Resource Centers (Healthy Baby Clubs) to address tobacco use with pregnant and post-partum women. It focuses on screening for tobacco use, and initiating a conversation with women about smoking Residents enrolled the NL Prescription Drug Program will receive assistance with the cost of NRTS for up to 12 continuous weeks Canada (PHAC): Other - HCCF projects with an education and public awareness component are adapted for their particular target groups.
1		Do these educational and public awareness programmes cover:
	1	health risks of tobacco consumption? Yes
	2	health risks of exposure to tobacco smoke? Yes
	3	benefits of the cessation of tobacco use and tobacco-free lifestyles?

	4	adverse economic consequences of tobacco production?
	·	No
	F	
	5	adverse economic consequences of tobacco consumption?
		Yes
	6	adverse environmental consequences of tobacco production?
		Yes
	7	adverse environmental consequences of tobacco consumption?
		Yes
1		awareness and participation of the following agencies and organizations in development and implementation of intersectoral programmes and strategies for tobacco control:
	1	public agencies?
		Yes
	2	nongovernmental organizations not affiliated with the tobacco industry?
		Yes
	3	private organizations?
		Yes
	4	
	4	other
		Yes
C2651		Please specify
		ON - Awareness is developed by - transfer payment organizations that deliver cessation services and are funded by the Ontario's Ministry of Health. Public Heath Units funded by the Ministry of Health also develop awareness within their catchment areas. BC - WHO, TFI, CS, PAHO, Professional Associations AB - Primary Care Clinics, Action on Smoking and Health, Canadian Cancer Society, Alberta Lung Association Canada - HCCF leverages funding from partners across various sectors in support of tobacco cessation. In addition, many types of organizations can apply for HCCF funding.
C266		Are the elaboration, management and implementation of communication, education, training and public awareness programmes guided by research and do they undergo pre-testing, monitoring and evaluation?
		Yes
1		Are appropriate and special training or sensitization and awareness programmes on tobacco control addressed to:
	1	health workers?
		Yes
	2	community workers?
		Yes
	3	social workers?
		Yes
	4	media professionals?
	4	
		Yes
	5	educators?

		Yes
	6	decision-makers?
		Yes
	7	administrators?
		Yes
	8	other
		Yes
C2671		Please specify
		AB – Health professional communications/training for pharmacists, primary care staff, AHS staff School-based curriculum supports for educators NL – OMSC training sessions provided to front lin health care staff Referral to smoking cessation services available for clinicians in the Electronic Medical Records System (EMR) provincially Healthy Students Healthy Schools Committee uses the comprehensive school health framework, development of policies, programs and supports for healthy eating, physical activity and the creation of smoke-free environments. Membership with the Pan-Canadian Joint Consortium for School Health (JCSH) supports the work of HSHS within the province. Canada - HC projects with a training or awareness component are adapted for their audience; Certified Tobacco Educators
C268		Please provide a brief description of the progress made in implementing Article 12 (Education, communication, training and public awareness) in the past two years or since submission of your last report.
		PEI - Since the last reporting period, PEI has implemented a universal Tobacco Cessation Program implementing WHOs Framework of Tobacco Control (cessation, prevention and protection). Funding has been dedicated to a universal cessation program (2019) - improved accessibility of tobacco cessation support, media campaigns, public promotions, developing specialized programs and initiatives (e.g., Pregnant Women and Caregivers; Workplace Wellness Smoking Cessation Support, Quit Your Way Youth Guide), resource development, ongoing prevention and enhanced protection initiatives. BC - Since January 2020, BC MOH has executed 5 flights of the youth anti- vaping campaign (Evapourate). Over the 5 flights, assets reached over 7 million and garnered over 74 million impressions. Print materials, including toolkit and posters, disseminated to all senior and junior high schools across BC. Reporting on activities prescribed in Section C26 presented challenges for Canada. Responsibility for education, communication, training and public awareness is shared between federal, provincial and territorial governments. While a number of activities have national application, there are some that are supported in select sub-national jurisdictions but not i others. AB - Implementation of low-moderate reach social media/ marketing campaigns. Implementation of ABQuits Covid communications/social media plan on tobacco, vaping and COVID 19. Development of a curriculum support resource and pilot/evaluation for grades 7-9 classrooms NL - Work is ongoing to expand the OMSC in further health facilities across the province Expanded the resources available for adults and youth on Bridgethegapp.ca Canada - HCCF funds various projects with components. See additional input document for program project descriptions (Annex 3).
C269		Have you utilized the "Guidelines for implementation of Article 12 of the WHO FCTC" when developing and implementing policies in this area?
00010		Yes
C2610		If you answered "Yes" to question C269 please provide details in the space below or refer t section E of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en Federal campaigns aim to raise awareness of the array and efficacy of quit aids, promoting available resources – helping to support norms conducive to support quitting smoking. Dissemination of resources / promoting access to services.
C2611		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
		BC – All campaign work referenced is in relation to anti-vaping promotion targeting youth (13-18), with additional message supports for parents (and other adult influencers) to talk to youth about the harms of vaping. Canada – See additional input document for program and project descriptions (Annex 3).

C27		Tobacco advertising, promotion and sponsorship Have you adopted and implemented, where appropriate, any legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes:
C271		instituting a comprehensive ban on all tobacco advertising, promotion and sponsorship?
		Yes
1		Does your ban cover:
	1	display and visibility of tobacco products at points of sales?
		Yes
	2	the domestic Internet?
		Yes
	3	the global Internet?
		Νο
	4	brand stretching and/or brand sharing?
		Yes
	5	product placement as a means of advertising or promotion?
		Yes
	6	the depiction of tobacco or tobacco use in entertainment media products?
	0	
		Yes
	7	tobacco sponsorship of international events or activities and/or participants therein?
		Yes
	8	contributions from tobacco companies to any other entity for "socially responsible causes and/or any other activities implemented under the umbrella of "corporate social responsibility" by the tobacco industry?
		No
	9	cross-border advertising, promotion and sponsorship originating from your territory?
		Yes
	10	the same forms of cross-border advertising, promotion and sponsorship entering your territory for which domestic regulation apply?
		Yes
C273		are you precluded by your constitution or constitutional principles from undertaking a comprehensive ban on tobacco advertising, promotion and sponsorship?
		N/A
C274		applying restrictions on all tobacco advertising, promotion and sponsorship?
		N/A
C275		applying restrictions on cross-border advertising, promotion and sponsorship originating from your territory with cross-border effects?
		N/A
C276		prohibiting those forms of tobacco advertising, promotion and sponsorship that promote a tobacco product by any means that are false, misleading, deceptive or likely to create an erroneous impression about its characteristics, health effects, hazards or emissions?

		N/A
C277		requiring that health or other appropriate warnings or messages accompany all tobacco advertising, promotion and sponsorship?
		N/A
C278		restricting the use of direct or indirect incentives that encourage the purchase of tobacco products by the public?
		N/A
C279		requiring the disclosure to relevant Government authorities of expenditures by the tobacco industry on advertising, promotion and sponsorship not yet prohibited?
		N/A
1		restricting tobacco advertising, promotion and sponsorship on:
	1	radio?
		N/A
	2	television?
		N/A
	3	print media?
		N/A
	4	the domestic Internet?
		N/A
	5	the global Internet?
		N/A
	6	other media?
		N/A
C27101		Please specify
1		restricting tobacco sponsorship of:
	1	international events and activities?
		N/A
	2	participants therein?
		N/A
C2712		cooperating with other Parties in the development of technologies and other means necessary to facilitate the elimination of cross-border advertising?
		No
C2713		imposing penalties for cross-border advertising equal to those applicable to domestic advertising, promotion and sponsorship originating from your territory in accordance with national law?
		No
C2714		Please provide a brief description of the progress made in implementing Article 13 (Tobacca advertising, promotion and sponsorship) in the past two years or since submission of your last report.

		BC - British Columbia implements the Tobacco and Vapour Products Control Act and Tobacco and Vapour and Products Control Regulation. ON - Display and promotion restrictions in retail environments have not changed since July 1, 2020.
C2715		Have you utilized the "Guidelines for implementation of Article 13 of the WHO FCTC" when developing and implementing policies in this area?
		Yes
C2716		If you answered "Yes" to question C2715 please provide details in the space below or refer to section F of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
		BC's laws and regulations surrounding tobacco are in alignment with Article 13.
C2717		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
		PEI does not allow any type of tobacco advertising or promotion in a place or premises where tobacco is sold at retail, in a place or premises where persons under the age of 21 are permitted access, restricts outdoor signs or anywhere that is visible from the outside of a business.
C28		Demand reduction measures concerning tobacco dependence and cessation Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C281		developing and disseminating appropriate, comprehensive and integrated guidelines based on scientific evidence and best practices?
		Yes
1		programmes to promote cessation of tobacco use, including:
	1	media campaigns emphasizing the importance of quitting?
		Yes
	2	programmes specially designed for underage girls and young women?
		Yes
	3	programmes specially designed for women?
		Yes
	4	programmes specially designed for pregnant women?
		Yes
	5	telephone quitlines?
		Yes
	6	local events, such as activities related to World No Tobacco Day or National No Smoking Day, if appropriate?
		Yes
	7	other?
		Yes
C2821		Please specify
		BC's quitline provider QuitNow undertakes advertising campaigns designed to raise awareness and emphasize the importance of quitting. They offer quit counselling tailored to the needs of their clients. Additionally, CAMH has guidelines to support quitting for many groups including Aboriginal Peoples, Pregnant and Breastfeeding women, and youth that can be found here: https://www.nicotinedependenceclinic.com/en/canadaptt/Pages/CAN-ADAPTT-Guidelines.aspx ON

		- Other programs include: digital support and internet advertising. These activities are carried out by transfer payment organizations (e.g., Centre for Addiction and Mental Health). AB - Cessation related social media campaigns including Reasons for Quitting, Men's Campaign, Smoking, Vaping and COVID-19; Co use of cannabis and tobacco; Increased in Cessation medication coverage during COVID pandemic Field kits and media releases for World No Tobacco Day and National Non Smoking Week. NL - Provincial campaign titled "Some Day to Quit Smoking" was used during NNSW in 2023, consisted of social media messaging shared by community partners and health professionals involved in cessation Smoker's Helpline utilizes telephone quit line as well as text and email options for tips to become or stay smoke-free Helping Women Live Smoke- Free Initiative supports Family Resource Centers (Healthy Baby Clubs) to address tobacco use with pregnant and post-partum women.
1		design and implementation of programmes aimed at promoting the cessation of tobacco use, in such locations as:
	1	educational institutions? Yes
	2	health-care facilities?
		Yes
	3	workplaces?
		Yes
	4	sporting environments?
		Yes
	5	other?
		Yes
C2831		Please specify
		BC - Under the Tobacco and Vapour Products Control Act and Regulation, owners, managers or lessees, are responsible for ensuring that their public and work places comply with the requirements for creating a tobacco and vapour free environment. More info can be found here: htt ps://www2.gov.bc.ca/gov/content/health/keeping-bc-healthy-safe/tobacco-vapour/requirements- under-tobacco-vapour-product-control-act-regulation/tobacco-vapour-free-places Educational Institutions: Under the Tobacco and Vapour Products Control Act all public and private kindergarten to Grade 12 schools in BC are required to be tobacco and vapour free. Health-care facilities: The legislation gives Health Authorities the discretion to implement designated outdoor smoking areas that allow tobacco or vapour product use. It is up to health authorities to decide if they will designate an area for the use of one, both or neither of these products. MB - The department's school-based Review and Rate program, where high school students select the best international anti-tobacco and vaping TV ads, provides an opportunity for education on the harms associated with smoking and vaping, and the benefits of quitting. Launched in April 2022, the Quit Smoking with Your Manitoba Pharmacist social impact bond is expected to enrol up to 4,500 people across the province over a three-year period. Smokers who are ready to quit will be supported by one of more than 500 Manitoba pharmacists who are trained in smoking cessation tools and supports. In February 2022, Manitoba announced it would be providing \$300.0 in new funding to expand Shared Health's Tobacco Quit Card and Counselling Program to all health regions. The program is now operational and provides nicotine replacement therapy (NRT) and cessation counselling to low income individuals who wish to quit smoking through primary care clinics. ON - Ontario's educational curriculum includes information about tobacco use. CREATE workplace cessation pilot program Provision of Cessation kits for use with individuals
1		inclusion of diagnosis and treatment of tobacco dependence and counselling services for cessation of tobacco use in national programmes, plans and strategies for:

		Yes
	2	health?
		Yes
	3	education?
		Yes
C285		inclusion of programmes on the diagnosis and treatment of tobacco dependence in your health-care system?
		Yes
1		Which structures in your health-care system provide programmes for the diagnosis and treatment of tobacco dependence?
	1	primary health care
		Yes
	2	secondary and tertiary health care
		Yes
	3	specialist health-care systems (please specify below)
		Yes
	4	specialized centres for cessation counselling and treatment of tobacco dependence
		Yes
	5	rehabilitation centres
		Yes
1		Are the services provided in these settings covered by public funding or reimbursement schemes?
	1	primary health care
		Fully
	2	secondary and tertiary health care
		Fully
	3	specialist health-care systems (please specify below)
		Fully
	4	specialized centres for cessation counselling and treatment of tobacco dependence
		Fully
	5	rehabilitation centres
		Fully
	6	other (please specify below)
		Partially
C287b		Please provide other details in the space below.
		MB - Quit Smoking with your Manitoba Pharmacist Social Impact Bond: Follow-up counselling sessions and up to \$100 worth of prescribed medications and nicotine replacement therapies will be offered over one year to support individuals in their journey to quit. Tobacco Quit Card and Counselling Program: Eligible Manitobans will receive a Quit Card redeemable at any Manitoba pharmacy to receive up to \$300 of nicotine replacement medication. AB - Integrated tobacco care

		pathway and pharmacotherapy order sets built in the provincial electronic medical record system (ConnectCare) for AHS Primary Care – physician is compensated for counselling but cessation medication coverage depends on whether or not patient has insurance coverage that includes cessation medication. Coverage for other health care providers to deliver cessation services if physician is part of a primary care network. Specialist Health Care Systems, Rehabilitation Centres and Mental Health Addiction Services– Health care provider counseling is covered but cessation medication coverage depends on whether or not patient has insurance coverage that includes cessation medication. Medication is covered while individual is an inpatient but not as ambulatory or outpatient. NL - Individuals can receive cessation counseling free from primary care providers and specialized centers however would have to purchase most NRTs
1		Which health and other professionals are involved in programmes offering treatment for tobacco dependence and counselling services? Health professionals including:
	1	physicians Yes
	2	dentists
		Yes
	3	family doctors Yes
	4	practitioners of traditional medicine
		Yes
	5	other medical professionals (please specify below)
		Yes
	6	nurses
		Yes
	7	midwives
		Yes
	8	pharmacists
		Yes
	9	Community workers
		Yes
	10	Social workers
		Yes
	11	other (please specify)
		Yes
1		training on tobacco dependence treatment incorporated into the curricula of health professional training at pre- and post-qualification levels at the following schools:
	1	medical?
		Yes
	2	dental?
		Yes
	3	nursing?
	5	

		Yes
	4	pharmacy?
		Yes
C2810		facilitating accessibility and/or affordability of pharmaceutical products for the treatment of tobacco dependence?
		Yes
C2811		Where and how can these products be legally purchased in your country?
		PEI - Pharmaceutical companies (smoking cessation pharmacotherapy products) - purchased through private pharmacies BC - Products are available through the BC Smoking Cessation Program or can be purchased in pharmacies. AB - pharmacies ON - Provincial pharmacies provide these products. Nicotine replacement therapy may be purchased legally in all retail settings. No prescription is required. Bupropion and varenicline are only available with a prescription and are sold at pharmacies. Cytisine may be purchased legally in all retail settings. No prescription is required. NB – Pharmacies Canada - Pharmacies and Health Centres, select products available as not limited by prescription only.
1		Which pharmaceutical products are legally available for the treatment of tobacco dependence in your jurisdiction?
	1	nicotine replacement therapy
		Yes
	2	bupropion
		Yes
	3	varenicline
		Yes
	4	other (please specify)
		Yes
1		Are the costs of these products covered by public funding or reimbursement?
	1	nicotine replacement therapy
		Fully
	2	bupropion
		Fully
	3	varenicline
		Fully
	4	other (please specify below)
		Fully
C2813b		Please provide other details in the space below.
		AB - No change since last report – public funding through specific government benefit programs MB - NRT= none, although included in limited programs like SIB and Quit Card: Yes fully, if family deductible is met or on EIA Varenicline: Yes, fully if family deductible is met or on EIA Other (please specify below) Nortriptyline and clonidine are fully covered if family deductible is met or on EIA. Note - federal programs like NIHB cover NRT for clients who are beneficiaries of those programs. PEI provides a universal Cessation Program PEI residents – covers 100% of the cost of pharmacotherapy products (therapy cessation) for maximum of 18 weeks once per year. MB - Quit Smoking with your Manitoba Pharmacist Social Impact Bond: Follow-up counselling sessions and up to \$100 worth of prescribed medications and nicotine replacement therapies will be offered over one year to support individuals in their journey to quit. Tobacco Quit Card and Counselling

	Program: Eligible Manitobans will receive a Quit Card redeemable at any Manitoba pharmacy to receive up to \$300 of nicotine replacement medication. ON - NRT is funded and available at no charge through Ontario Ministry of Health programs. Other smoking cessation drugs (e.g., bupropion) may be covered by the Ontario Drug Benefit Plan, which is available to those 65 and older, those 24 and under (not covered by a.private plan), as well as people on social assistance. NL - An individual registered under the NL Prescription Drug Program (NLPDP) Access, Foundation (Income Support), or 65+ plans can receive up to 12 continuous weeks (84 days) of one prescription drug (Champix® or Zyban®) or nicotine replacement product (patch, gum, lozenge or inhaler) within a 365 day period.
C2814	Please provide a brief description of the progress made in implementing Article 14 (Demand reduction measures concerning tobacco dependence and cessation) in the past two years or since submission of your last report.
	PEI - Since last reporting period, PEI has implemented a universal Tobacco Cessation Program implementing WHOs Framework of Tobacco Control (cessation, prevention and protection). Funding has been dedicated to a universal cessation program (2019) - improved accessibility of tobacco cessation support, media campaigns, public promotions, specialized programs and initiatives, and enhanced protection and prevention initiatives. BC - British Columbia takes a comprehensive approach to controlling tobacco. This approach is described in British Columbia's Tobacco Control Strategy: Targeting Our Efforts (PDF, 774KB). The strategy has a focus on three key areas: • Prevention programs - to protent Strate (Control and prevention) adults from starting to use tobacco. • Cessation programs - to encourage and assist tobacco users to reduce and quit their use of tobacco products. • Protection programs - to protect British Columbians, particularly infants and children, from exposure to second-hand smoke. Programs available to help people quit smoking in BC include Quitnow, the BC Smoking Cessation Program and Talk Tobacco. AB - From May 2020 to December 2022, barrier free quiting medications (NRT, Buproprion, Varenicline) were provided to individuals participating in cessation counselling through a Certified Tobacco Educator or HelpLine Counsellor as part of an AlbertaQuits COVID project. Group cessation programs were transitioned to virtual platforms during the pandemic. Integrated tobacco care pathway and pharmacotherapy order sets were built in the provincial electronic medical record system (ConnectCare) for AHS MB - Since the submission of Manitoba's last report, Manitoba has implemented two new cessation rung shared Health's Tobacco Quit Card and Counselling Program to all health regions. The program is now operational and provides nicotine replacement therapy (NRT) and cessation counselling towain to a protect with theramacist-led interventions, products and counselling to wis operational and provides nicotine replacement
C2815	Have you utilized the "Guidelines for implementation of Article 14 of the WHO FCTC" when developing and implementing policies in this area? Yes
C2816	Please provide details in the space below or refer to section G of the additional questionnaire. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
	ON - Ontario's Ministry of Health follows a number of the guidelines including: Establish system components The Ministry has a public health insurance (OHIP) billing code for providing cessation support. Also, the Ministry provides stable funding for tobacco cessation and dependence treatment programs. Integrate brief advice into existing health-care systems The Ministry funds the Ottawa Model for Smoking Cessation which supports clinicians in identifying and providing evidence-based interventions to smokers. The ministry also funds the Smoking Treatment for Ontario Patients (STOP) program which provides cessation support through the nicotine dependency clinic based in the Centre for Addiction and Mental Health. In addition, the Ministry ofHealth provides funding for Aboriginal Health Access Centres to support cessation services specifically for Indigenous peoples. Create capacity for tobacco cessation support and tobacco dependence The Ministry supports a free quit line service and provides nicotine replacement therapy at no charge through its cessation services programs. NL - Implementation of the Smoking

	Cessation Program under the NLPDP helps ensure that treatment for tobacco should be widely available, accessible and affordable
C2817	If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.

C3. MEASURES RELATING TO THE REDUCTION OF THE SUPPLY OF TOBACCO

C3	With reference to Articles 15–17
C31	Illicit trade in tobacco products Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C311	requiring marking of all unit packets and packages of tobacco products and any outside packaging of such products to assist in determining the origin of the product?
	Yes
C312	requiring marking of all unit packets and packages of tobacco products and any outside packaging of such products to assist in determining whether the product is legally sold on the domestic market?
	Yes
C313	requiring that unit packets and packages of tobacco products for retail and wholesale use that are sold on the domestic market carry the statement: "Sales only allowed in" or carry any other effective marking indicating the final destination of the product?
	Yes
C314	developing a practical tracking and tracing regime that would further secure the distribution system and assist in the investigation of illicit trade?
	No
C315	requiring that marking is presented in legible form and/or appears in the principal language or languages of the country?
	Yes
C316	requiring the monitoring and collection of data on cross-border trade in tobacco products, including illicit trade?
	Yes
C317	facilitating the exchange of this information among customs, tax and other authorities, as appropriate, and in accordance with national law and applicable bilateral and multilateral agreements?
	Yes
C318	enacting or strengthening legislation, with appropriate penalties and remedies, against illici trade in tobacco products, including counterfeit and contraband cigarettes?
	No
C319	requiring that confiscated manufacturing equipment, counterfeit and contraband cigarettes and other tobacco products derived from illicit trade are destroyed, using environment- friendly methods where possible, or disposed of in accordance with national law?
	Yes
C3110	adopting and implementing measures to monitor, document and control the storage and distribution of tobacco products held or moving under suspension of taxes or duties?
	Yes
C3111	enabling the confiscation of proceeds derived from illicit trade in tobacco products?
	Yes
C3112	promoting cooperation between national agencies and relevant regional and international
00112	intergovernmental organizations in investigations, prosecutions and proceedings, with a view to eliminating illicit trade in tobacco products, with special emphasis on cooperation a regional and subregional levels?

		Yes
C3113		licensing or other actions to control or regulate production and distribution in order to prevent illicit trade?
		Yes
C3114		Please provide a brief description of the progress made in implementing Article 15 (Illicit trade in tobacco products) in the past two years or since submission of your last report.
C3115		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C32		Sales to and by minors Have you adopted and implemented, where appropriate, legislative executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C321		prohibiting the sales of tobacco products to minors?
		Yes
C321a		Please specify the legal age:
		18
C322		requiring that all sellers of tobacco products place a clear and prominent indicator inside their point of sale about the prohibition of tobacco sales to minors?
		No
C323		requiring that, in case of doubt, each seller of tobacco products requests that the purchase provides appropriate evidence of having reached full legal age?
		Yes
C324		banning the sale of tobacco products in any manner by which they are directly accessible, such as open store shelves?
		Yes
C325		prohibiting the manufacture and sale of sweets, snacks, toys or any other objects in the form of tobacco products which appeal to minors?
		No
C326		prohibiting the sale of tobacco products from vending machines?
		Yes
C327		Do you ensure that tobacco vending machines are not accessible to minors and/or do not promote the sale of tobacco products to minors?
		N/A
1		prohibiting and/or promoting the prohibition of the distribution of free tobacco products:
	1	to the public?
		Yes
	2	to minors?
		Yes
C329		
0328		prohibiting the sale of cigarettes individually or in small packets?

		Yes
C3210		providing for penalties against sellers and distributors in order to ensure compliance?
		Yes
C3211		prohibiting the sales of tobacco products by minors?
		Yes
C3212		Please provide a brief description of the progress made in implementing Article 16 (Sales to and by minors) in the past two years or since submission of your last report.
		The legal age varies by province (18-21 years of age). At a national level, the minimum legal age o 18 is set out in the Tobacco and Vaping Products Act. Since the last reporting period, PEI has raised their minimum legal age in the province to 21 years old.
C3213		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C33		Provision of support for economically viable alternative activities Have you adopted and implemented, where appropriate, measures or programmes on any of the following:
1		promoting economically viable and sustainable alternatives for:
	1	tobacco growers?
		No
	2	tobacco workers?
		No
	3	tobacco individual sellers?
		No
C332		Please provide a brief description of the progress made in implementing Article 17 (Provision of support for economically viable alternative activities) in the past two years or since submission of your last report.
C333		Have you utilized the "Policy options and recommendations on economically sustainable alternatives to tobacco growing (in relation to Articles 17 and 18 of the WHO FCTC)" when developing and implementing policies in this area?
0004		No
C334		Please provide details in the space below or refer to section I of the additional questionnaire. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
C335		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
		Note: There are no tobacco-specific programs under Canada's current national agriculture policy framework (Canadian Agricultural Partnership) under either the grant and contribution programs administered directly by Agriculture and Agri-Food Canada or under programs being delivered by provinces and territories with federally and provincially cost shared funds.

C4. OTHER MEASURES AND POLICIES

C4		With reference to Articles 18–21
C41		Protection of the environment and the health of persons Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
1		implementing measures in respect of tobacco cultivation within your territory, which take into consideration:
	1	the protection of the environment?
	2	the health of persons in relation to the environment?
1		implementing measures in respect of tobacco manufacturing within your territory, which take into consideration:
	1	the protection of the environment? Yes
	2	the health of persons in relation to the environment?
		Yes
C413		Please provide a brief description of the progress made in implementing Article 18 (Protection of the environment and the health of persons) in the past two years or since submission of your last report.
		Health Canada's Pest Management Regulatory Agency regulates pesticides for all agricultural crops, including tobacco. In doing so, it takes health and the environment into consideration. While the Tobacco and Vaping Products Act does not provide environmental measures with respect to manufacturing, Canada has extensive national and sub-national legislation and regulations that provide for the protection of the environment, labour standards, and measures that protect the health of persons in relation to the environment.
C414		Have you utilized the "Policy options and recommendations on economically sustainable alternatives to tobacco growing (in relation to Articles 17 and 18 of the WHO FCTC)" when developing and implementing policies in this area?
		No
C415		If you answered "Yes" to question C414 please provide details in the space below or refer to section I of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
C416		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C42		Liability Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programme on any of the following:
SQ001		Does your tobacco control legislation contain measures regarding criminal liability for any

		violations of that tobacco control legislation?
	SQ001	Yes
SQ001		Do you have separate criminal liability provisions in relation to tobacco control (outside of the tobacco control legislation)?
	SQ001	
		Yes
SQ001		Do you have any civil liability measures that are specific to tobacco control?
	SQ001	
		Yes
SQ001		Do you have any general civil liability provisions that could apply to tobacco control?
	SQ001	
		Yes
SQ001		Do you have civil or criminal liability provisions that provide for compensation for adverse health effects and/or for reimbursement of medical, social or other relevant costs?
	SQ001	
		No
SQ001		?Has any person in your jurisdiction launched any criminal and/or civil liability action, including compensation where appropriate, against any tobacco company in relation to any adverse health effect caused by tobacco use?
	SQ001	
		Yes
SQ001		Have you taken, as appropriate, any legislative, executive, administrative and/or other action against the tobacco industry for full or partial reimbursement of medical, social and other relevant costs related to tobacco use in your jurisdiction?
	SQ001	
		No
C428		Please provide a brief description of any progress made, as appropriate, in implementing Article 19 (Liability) in the past two years or since submission of your last report.
		Tobacco liability/cost recovery cases in Canada are pursued at the sub-national (Provincial/Territorial) level, where constitutional authority for health care resides. All ten provinces have brought actions against tobacco companies to recover past and future health care costs associated with tobacco-related diseases. The federal government was named as a 'third party defendant' by the tobacco industry defendants in these the actions brought by British Columbia, Ontario, and New Brunswick. However, in 2011, the Supreme Court of Canada struck out Imperial Tobacco Canada Ltd.'s third party claim in the British Columbia cost recovery action. Following this decision, the federal government was removed as a party from the Ontario and New Brunswick cases as well. Class action lawsuits have also been launched against the tobacco industry by private citizens in Canada (Blais/Létourneau, and Knight litigation) in two provinces. Similar to the

1		a national system for epidemiological surveillance of:
		Yes
C432		training and support for all persons engaged in tobacco control activities, including research, implementation and evaluation?
C4311		Please specify
		No
	7	identification of alternative livelihoods?
		Yes
	6	identification of effective programmes for the treatment of tobacco dependence?
		Yes
	5	the determinants and consequences of exposure to tobacco smoke?
		Yes
	4	tobacco use among women, with special regard to pregnant women?
	_	Yes
	3	social and economic indicators related to tobacco consumption?
	2	consequences of tobacco consumption? Yes
	2	Yes
	1	determinants of tobacco consumption?
1		developing and/or promoting research that addresses:
C43		Research, surveillance and exchange of information Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C429		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
		party' (called an "Action in Warranty" in Quebec) in these actions. However, following the same Supreme Court of Canada 2011 decision mentioned above, these third party claims have been struck. To our knowledge, the Government of Canada has not joined or participated in any legal action against any Tobacco company in relation to the harm caused by tobacco usage since November 4, 2015. Given that the request is broader, we also did a quick case law database search and didn't find anything. This is not really surprising since the big three tobacco companies (Imperial Tobacco, JTI-MacDonald and Rothmans, Benson and Hedges) are in creditor protection - and the order currently stays all proceedings against these companies. For your information, following the Quebec Court of Appeal's decision on March 1, 2019 in the Blais and Létourneau class actions, which confirmed the award of approximately \$15 billion to class members, Imperial Tobacco, JTI-MacDonald and Rothmans Benson and Hedges sought creditor protection under the Companies' Creditors Arrangement Act (CCAA). In March 2019 the Ontario Superior Court of Justice issued orders pursuant to the CCAA and stayed all proceedings across Canada against these three companies. The most recent stay of proceedings expires on March 31, 2023. Essentially the stay prevents continuing pending litigation and commencing new litigation, subject to some conditions outlined in the order, such as obtaining the court's permission.

I	I	
		Yes
	2	determinants of tobacco consumption?
		Yes
	3	consequences of tobacco consumption?
		No
	4	social, economic and health indicators related to tobacco consumption?
		Yes
	5	exposure to tobacco smoke?
		Yes
C4331		Please specify
C434		Please list all surveys, including the year of the survey, that you have undertaken in the past.
		Regular measurements of the prevalence of tobacco use by the Canadian population are obtained by the Canadian Tobacco and Nicotine Survey which is the current general population survey for those aged 15 years and older, and for school-aged children in grades 7-12, the Canadian Student Tobacco, Alcohol and Drugs Survey. The Canadian Tobacco and Nicotine Survey was developed to provide data on tobacco and vaping product use by Canadians aged 15 years and older. It serves as a temporary replacement for the Canadian Tobacco, Alcohol and Drugs Survey, which was last implemented in 2017. The Canadian Student Tobacco, Alcohol and Drugs Survey provides timely and accurate monitoring of the tobacco use in school aged children (grades 7-12). The Survey contributes an essential input to the development of sound and effective tobacco control policies and programs.
C435		Does your country have any plans to repeat any of the above or to undertake a new tobacco survey within three to five years of your last survey? Please provide details in the space below.
		Yes, the surveys are conducted on a biannual basis.
1		regional and global exchange of publicly available national:
	1	scientific, technical, socioeconomic, commercial and legal information?
		Yes
	2	information on the practices of the tobacco industry?
		Yes
	3	information on the cultivation of tobacco?
		Yes
1		an updated database of:
	1	laws and regulations on tobacco control?
		Yes
	2	information about the enforcement of laws on tobacco control?
		Yes
	3	pertinent jurisprudence?
		Yes

C438	Please provide a brief description of the progress made in implementing Article 20 (Research, surveillance and exchange of information) in the past two years or since submission of your last report.
C439	If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below (e.g. whether you included information on WHO FCTC implementation in your Voluntary National Review (VNR) on the Sustainable Development Goals (SDGs), related to target 3.a).

D. INTERNATIONAL COOPERATION AND ASSISTANCE

D0		Pursuant to Article 21.1(c) and in accordance with Article 26, have you either provided or received financial or technical assistance (be it through unilateral, bilateral, regional, subregional or other multilateral channels, including relevant regional and international intergovernmental or nongovernmental organizations and financial and development institutions) for the development and strengthening of multisectoral, comprehensive tobacco control programmes of developing country Parties and Parties with economies in transition in any of the following areas:
1		development, transfer and acquisition of technology, knowledge, skills, capacity and expertise related to tobacco control?
	1	Assistance provided
		Yes
	2	Assistance received
		No
1		provision of technical, scientific, legal and other expertise to establish and strengthen national tobacco control strategies, plans and programmes?
	1	Assistance provided
		Yes
	2	Assistance received
	_	No
1		appropriate training or sensitization programmes for appropriate personnel in accordance with Article 12?
	1	Assistance provided
		No
	2	Assistance received
		No
1		provision of the necessary material, equipment and supplies, as well as logistic support, for tobacco control strategies, plans and programmes?
	1	Assistance provided
		No
	2	Assistance received
		No
1		identification of methods for tobacco control, including comprehensive treatment of nicotine addiction?
	1	Assistance provided
		No
	2	Assistance received
	I	1 I

		No
1		promotion of research to increase the affordability of comprehensive treatment of nicotine addiction?
	1	Assistance provided
		No
	2	Assistance received
		No
D7		Please identify the Party or Parties from which assistance was received or to which assistance was provided.
		Technical assistance was provided to different Parties via exchanges in the Global Tobacco Regulators Forum
D8		Please provide information about any assistance provided or received in the space below, including any support received from nongovernmental organizations (please, specify).
		Financial assistance was provided the International Health Grants Program (IHGP) for the proposal "Enhancing Healthcare Systems, Tobacco Control Amid Covid-19." \$CAD 105,220 was provided to the African Tobacco Control Alliance to lead this project (in fiscal year 2022-23)
D9		If you have not received or provided assistance in any of the aforementioned areas, please identify any financial or technical assistance that may be under consideration, if appropriate.
D10		Have you encouraged relevant regional and international intergovernmental organizations and financial and development institutions in which you are represented to provide financial assistance for developing country Parties and for Parties with economies in transition to assist them in meeting their obligations under the Convention? No
D11		Please provide details in the space below.

E. PRIORITIES AND COMMENTS

E1		What are the priorities for implementation of the WHO Framework Convention on Tobacco Control in your jurisdiction?
		Article 5.3
E2		Have you identified any specific gaps between the resources available and the needs assessed for implementing the WHO Framework Convention on Tobacco Control?
		No
E3		Please provide details in the space below.
E4		What, if any, are the constraints or barriers, other than lack of resources, you have encountered in implementing the Convention?
1		Do you have any of the following products available on your national tobacco market?
	1	smokeless tobacco products
		Yes
	2	water pipe tobacco
		Yes
	3	Electronic Nicotine Delivery Systems (ENDS)
		Yes
	4	Electronic Non-Nicotine Delivery Systems (ENNDS)
		Yes
	5	heated tobacco products (HTPs)
		Yes
1		Have you adopted and implemented any policy or regulation that is specific to the following tobacco products?
	1	smokeless tobacco products
		Yes
	2	water pipe tobacco
		Yes
	3	Electronic Nicotine Delivery Systems (ENDS)
		Yes
	4	Electronic Non-Nicotine Delivery Systems (ENNDS)
		Yes
	5	heated tobacco products (HTPs)
		Yes
E7		If you have any relevant information related to questions E5 and E6, please provide details in the space below.
		There are specific health labelling requirements for chewing tobacco, oral snuff and nasal snuff. Also, plain packaging requirements apply to all tobacco products, but not ENDS or ENNDS.

E8	Do you have a costed national tobacco control plan or strategy?
	Yes
E81	If you answered "Yes" to question E8, is this costed national tobacco control plan or strategy fully funded?
	Yes
E82	Please attach the costed plan or strategy here.
	FCTC Reporting Annex 4 - Canada's tobacco control budgets.pdf
E9	Please provide the government's expenditure on tobacco control, for the latest year available, in your country's currency.
	\$45.16 million (\$CAD, April 1, 2021 to March 31, 2022) - Please see Annex 5
E10	Have you adopted and implemented any national legislative, executive, administrative and/or other measures that go beyond the requirements of the Convention in line with Article 2.1 (e.g, endgame strategies, smoke-free generations, tobacco free villages or cities)?
	No
E101	If you answered "Yes" to question E10, please provide details.
E11	Please attach any documentation relevant to any sections of the reporting instrument.
	FCTC Reporting Annex 1 - Question B61.pdf
	FCTC reporting Annex 2 - Question B83.pdf FCTC reporting Annex 3 - Additional PHAC input for Core Questionnaire of the WHO FCTC Mar 3
	2023.pdf FCTC Reporting Annex 5 - Question E9 Tobacco control spending 2021-22.pdf
E12	Please provide any other relevant information not covered elsewhere that you consider important.
E13	Your suggestions for further development and revision of the reporting instrument:
	As mentioned, changing language to men/women and boys/girls throughout rather than male/female. Breaking up into smaller sections would be helpful in order to avoid timing out during submission. Many thanks!